1
|
Gonnelli S, Briot K, Cormier C, Teboul S, Roux C, Koumakis E. Multiple brown tumors: a bone complication due to long-term untreated pseudohypoparathyroidism. Osteoporos Int 2024; 35:195-199. [PMID: 37644196 DOI: 10.1007/s00198-023-06878-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/02/2023] [Accepted: 07/31/2023] [Indexed: 08/31/2023]
Abstract
Bone lytic lesions are a possible complication of pseudohypoparathyroidism type 1B, in undertreated adult patients. Whole body [18F] F-fluorocholine PET/CT is a useful imaging tool to assess brown tumor progression in this context. We describe the case of a 33-year-old woman, referred for the diagnostic evaluation of lytic bone lesions of the lower limbs, in the context of asymptomatic pseudohypoparathyroidism. She had been treated with alfacalcidol and calcium during her childhood. Treatment was discontinued at the age of 18 years old because of the lack of symptoms. A femur biopsy revealed a lesion rich in giant cells, without malignancy, consistent with a brown tumor. Laboratory tests showed a parathyroid level at 1387 pg/ml (14-50). Whole-body Fluorocholine PET/CT revealed hypermetabolism of bone lesions. The final diagnosis was brown tumors related to hyperparathyroidism complicating an untreated pseudohypoparathyroidism. Genetic testing confirmed PHP type 1B. Pseudohypoparathyroidism with radiographic evidence of hyperparathyroid bone disease, is a very rare condition due to parathyroid hormone resistance in target organs, i.e., kidney resistance, but with conserved bone cell sensitivity. It has been reported in only a few cases of pseudohypoparathyroidism type Ib. Long-term vitamin D treatment was required to correct bone hyperparathyroidism. With this rationale, the patient was treated with calcium, alfacalcidol, and cholecalciferol. One-year follow-up showed complete resolution of pain, improvement in serum calcium, and regression of bone lesions on [18F]F-fluorocholine PET/CT. This case illustrates the usefulness of [18F]F-fluorocholine PET/CT for the imaging of brown tumors in pseudohypoparathyroidism type 1B, and emphasizes the importance of calcium and vitamin D treatment in adult patients, to avoid the deleterious effects of high parathyroid hormone on skeletal integrity.
Collapse
Affiliation(s)
- S Gonnelli
- Université de Paris-APHP.Centre, Service de Rhumatologie, Hôpital Cochin, Centre de Référence des Maladies Rares du Métabolisme Phospho-calcique, Paris, France
| | - K Briot
- Université de Paris-APHP.Centre, Service de Rhumatologie, Hôpital Cochin, Centre de Référence des Maladies Rares du Métabolisme Phospho-calcique, Paris, France
| | - C Cormier
- Université de Paris-APHP.Centre, Service de Rhumatologie, Hôpital Cochin, Centre de Référence des Maladies Rares du Métabolisme Phospho-calcique, Paris, France
| | - S Teboul
- Université de Paris-APHP.Centre, Service de Rhumatologie, Hôpital Cochin, Centre de Référence des Maladies Rares du Métabolisme Phospho-calcique, Paris, France
| | - C Roux
- Université de Paris-APHP.Centre, Service de Rhumatologie, Hôpital Cochin, Centre de Référence des Maladies Rares du Métabolisme Phospho-calcique, Paris, France
| | - E Koumakis
- Université de Paris-APHP.Centre, Service de Rhumatologie, Hôpital Cochin, Centre de Référence des Maladies Rares du Métabolisme Phospho-calcique, Paris, France.
- INSERM UMR 1163, Imagine Institute, Paris, France.
| |
Collapse
|
2
|
Péros JP, Launay A, Peyrière A, Berger G, Roux C, Lacombe T, Boursiquot JM. Species relationships within the genus Vitis based on molecular and morphological data. PLoS One 2023; 18:e0283324. [PMID: 37523393 PMCID: PMC10389703 DOI: 10.1371/journal.pone.0283324] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/14/2022] [Accepted: 03/07/2023] [Indexed: 08/02/2023] Open
Abstract
The grape genus Vitis L. includes the domesticated V. vinifera, which is one of the most important fruit crop, and also close relatives recognized as valuable germplasm resources for improving cultivars. To resolve some standing problems in the species relationships within the Vitis genus we analyzed diversity in a set of 90 accessions comprising most of Vitis species and some putative hybrids. We discovered single nucleotide polymorphisms (SNPs) in SANGER sequences of twelve loci and genotyped accessions at a larger number of SNPs using a previously developed SNP array. Our phylogenic analyses consistently identified: three clades in North America, one in East Asia, and one in Europe corresponding to V. vinifera. Using heterozygosity measurement, haplotype reconstruction and chloroplast markers, we identified the hybrids existing within and between clades. The species relationships were better assessed after discarding these hybrids from analyses. We also studied the relationships between phylogeny and morphological traits and found that several traits significantly correlated with the phylogeny. The American clade that includes important species such as V. riparia and V. rupestris showed a major divergence with all other clades based on both DNA polymorphisms and morphological traits.
Collapse
Affiliation(s)
- Jean-Pierre Péros
- UMR AGAP Institut, CIRAD, INRAE, Institut Agro, University of Montpellier, Montpellier, France
| | - Amandine Launay
- UMR AGAP Institut, CIRAD, INRAE, Institut Agro, University of Montpellier, Montpellier, France
| | - André Peyrière
- UMR AGAP Institut, CIRAD, INRAE, Institut Agro, University of Montpellier, Montpellier, France
| | - Gilles Berger
- UMR AGAP Institut, CIRAD, INRAE, Institut Agro, University of Montpellier, Montpellier, France
| | - Catherine Roux
- UMR AGAP Institut, CIRAD, INRAE, Institut Agro, University of Montpellier, Montpellier, France
| | - Thierry Lacombe
- UMR AGAP Institut, CIRAD, INRAE, Institut Agro, University of Montpellier, Montpellier, France
| | - Jean-Michel Boursiquot
- UMR AGAP Institut, CIRAD, INRAE, Institut Agro, University of Montpellier, Montpellier, France
| |
Collapse
|
3
|
Sichel V, Sarah G, Girollet N, Laucou V, Roux C, Roques M, Mournet P, Cunff LL, Bert P, This P, Lacombe T. Chimeras in Merlot grapevine revealed by phased assembly. BMC Genomics 2023; 24:396. [PMID: 37452318 PMCID: PMC10347889 DOI: 10.1186/s12864-023-09453-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/04/2022] [Accepted: 06/09/2023] [Indexed: 07/18/2023] Open
Abstract
Chimerism is the phenomenon when several genotypes coexist in a single individual. Used to understand plant ontogenesis they also have been valorised through new cultivar breeding. Viticulture has been taking economic advantage out of chimeras when the variant induced an important modification of wine type such as berry skin colour. Crucial agronomic characters may also be impacted by chimeras that aren't identified yet. Periclinal chimera where the variant has entirely colonised a cell layer is the most stable and can be propagated through cuttings. In grapevine, leaves are derived from both meristem layers, L1 and L2. However, lateral roots are formed from the L2 cell layer only. Thus, comparing DNA sequences of roots and leaves allows chimera detection. In this study we used new generation Hifi long reads sequencing, recent bioinformatics tools and trio-binning with parental sequences to detect periclinal chimeras on 'Merlot' grapevine cultivar. Sequencing of cv. 'Magdeleine Noire des Charentes' and 'Cabernet Franc', the parents of cv. 'Merlot', allowed haplotype resolved assembly. Pseudomolecules were built with a total of 33 to 47 contigs and in few occasions a unique contig for one chromosome. This high resolution allowed haplotype comparison. Annotation was transferred from PN40024 VCost.v3 to all pseudomolecules. After strong selection of variants, 51 and 53 'Merlot' specific periclinal chimeras were found on the Merlot-haplotype-CF and Merlot-haplotype-MG respectively, 9 and 7 been located in a coding region. A subset of positions was analysed using Molecular Inversion Probes (MIPseq) and 69% were unambiguously validated, 25% are doubtful because of technological noise or weak depth and 6% invalidated. These results open new perspectives on chimera detection as an important resource to improve cultivars through clonal selection or breeding.
Collapse
Affiliation(s)
- V. Sichel
- UMR AGAP Institut, Univ Montpellier, CIRAD, INRAE, Institut Agro, Montpellier, F-34398 France
| | - G. Sarah
- UMR AGAP Institut, Univ Montpellier, CIRAD, INRAE, Institut Agro, Montpellier, F-34398 France
- UMT Geno-Vigne®, IFV-INRAE-Institut Agro, Montpellier, F-34398 France
| | - N. Girollet
- EGFV, Université de Bordeaux, Bordeaux-Sciences Agro, INRAe, ISVV, 210 Chemin de Leysotte, F-33882 Villenave d’Ornon, France
| | - V. Laucou
- UMR AGAP Institut, Univ Montpellier, CIRAD, INRAE, Institut Agro, Montpellier, F-34398 France
- UMT Geno-Vigne®, IFV-INRAE-Institut Agro, Montpellier, F-34398 France
| | - C. Roux
- UMR AGAP Institut, Univ Montpellier, CIRAD, INRAE, Institut Agro, Montpellier, F-34398 France
- UMT Geno-Vigne®, IFV-INRAE-Institut Agro, Montpellier, F-34398 France
| | - M. Roques
- Institut Français de la Vigne et du Vin, Montpellier, F-34398 France
- UMT Geno-Vigne®, IFV-INRAE-Institut Agro, Montpellier, F-34398 France
| | - P. Mournet
- UMR AGAP Institut, Univ Montpellier, CIRAD, INRAE, Institut Agro, Montpellier, F-34398 France
- UMR AGAP Institut, CIRAD, Montpellier, F-34398 France
| | - L. Le Cunff
- Institut Français de la Vigne et du Vin, Montpellier, F-34398 France
- UMT Geno-Vigne®, IFV-INRAE-Institut Agro, Montpellier, F-34398 France
| | - P.F. Bert
- EGFV, Université de Bordeaux, Bordeaux-Sciences Agro, INRAe, ISVV, 210 Chemin de Leysotte, F-33882 Villenave d’Ornon, France
| | - P. This
- UMR AGAP Institut, Univ Montpellier, CIRAD, INRAE, Institut Agro, Montpellier, F-34398 France
- UMT Geno-Vigne®, IFV-INRAE-Institut Agro, Montpellier, F-34398 France
| | - T. Lacombe
- UMR AGAP Institut, Univ Montpellier, CIRAD, INRAE, Institut Agro, Montpellier, F-34398 France
- UMT Geno-Vigne®, IFV-INRAE-Institut Agro, Montpellier, F-34398 France
| |
Collapse
|
4
|
Artico M, Roux C, Peruch F, Mingotaud AF, Montanier CY. Grafting of proteins onto polymeric surfaces: A synthesis and characterization challenge. Biotechnol Adv 2023; 64:108106. [PMID: 36738895 DOI: 10.1016/j.biotechadv.2023.108106] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/11/2022] [Revised: 01/26/2023] [Accepted: 01/30/2023] [Indexed: 02/05/2023]
Abstract
This review aims at answering the following question: how can a researcher be sure to succeed in grafting a protein onto a polymer surface? Even if protein immobilization on solid supports has been used industrially for a long time, hence enabling natural enzymes to serve as a powerful tool, emergence of new supports such as polymeric surfaces for the development of so-called intelligent materials requires new approaches. In this review, we introduce the challenges in grafting protein on synthetic polymers, mainly because compared to hard surfaces, polymers may be sensitive to various aqueous media, depending on the pH or reductive molecules, or may exhibit state transitions with temperature. Then, the specificity of grafting on synthetic polymers due to difference of chemical functions availability or difference of physical properties are summarized. We present next the various available routes to covalently bond the protein onto the polymeric substrates considering the functional groups coming from the monomers used during polymerization reaction or post-modification of the surfaces. We also focus our review on a major concern of grafting protein, which is avoiding the potential loss of function of the immobilized protein. Meanwhile, this review considers the different methods of characterization used to determine the grafting efficiency but also the behavior of enzymes once grafted. We finally dedicate the last part of this review to industrial application and future prospective, considering the sustainable processes based on green chemistry.
Collapse
Affiliation(s)
- M Artico
- Laboratory IMRCP, CNRS UMR 5623, University Paul Sabatier, Toulouse, France; TBI, Université de Toulouse, CNRS, INRAE, INSA, Toulouse, France
| | - C Roux
- Laboratory IMRCP, CNRS UMR 5623, University Paul Sabatier, Toulouse, France
| | - F Peruch
- Univ. Bordeaux, CNRS, Bordeaux INP, LCPO, UMR 5629, Pessac, France
| | - A-F Mingotaud
- Laboratory IMRCP, CNRS UMR 5623, University Paul Sabatier, Toulouse, France.
| | - C Y Montanier
- TBI, Université de Toulouse, CNRS, INRAE, INSA, Toulouse, France.
| |
Collapse
|
5
|
Belo-Kibabu S, Bottois C, Dumas S, Hubert J, Molto A, Roux C, Dougados M, Conort O. [Implementation, of multidisciplinary consultations for patients with inflammatory arthritis and treated with subcutaneous biologic DMARDs: Assessment at one year and outlook]. Ann Pharm Fr 2023; 81:370-379. [PMID: 36049544 DOI: 10.1016/j.pharma.2022.08.011] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/17/2021] [Revised: 07/18/2022] [Accepted: 08/23/2022] [Indexed: 10/15/2022]
Abstract
INTRODUCTION Biologics (bDMARDs) have revolutionized the prognosis of patients with inflammatory arthritis, but are not without serious side effects. The patient must be able to identify them, acquire self-care abilities or skills and adhere to their treatment. Multidisciplinary consultations, including a pharmaceutical consultation could improve the care of these patients. The pharmaceutical presence make it easier to switch to a biosimilar with etended patient support thanks to the community-hospital network. The return on investment is possible thanks to the more frequent use of biosimilars and the pricing of this type of consultation by the "Forfait de Prestation Intermédiaire". METHODOLOGY Eligible patients are patients with rheumatoid arthritis or spondyloarthritis, treated with subcutaneous bDMARDs. The criteria assessed were patient's knowledge of their biotherapy using the Biosecure score, their medication adherence using the CQR-5, the total of switch to biosimilars perform and the financial statement of the consultations. An assessment of the actions deployed for the community-hospital network. RESULTS Two hundred and ninety-five patients (47.4%) benefited multidisciplinary consultation. The mean score of the Biosecure score was 69.6/100 (moderate knowledge) and 261 patients (88.5%) were highly adherent. 57 patients (73%) accepted the switch to biosimilar. 197 pharmacy were contacted, all of witch for patients who receive the switch. Overall patient's satisfaction was 26.9/28. CONCLUSION Multidisciplinary consultations with involvement of the pharmacist should optimized patient care and the management of outpatients treated with bDMARDs. Patients have already expressed their satisfaction with this course of care and the return on investment is positive.
Collapse
Affiliation(s)
- S Belo-Kibabu
- Service de Pharmacie Clinique, hôpitaux universitaire Paris Centre-Site Cochin, 27, rue du Faubourg-Saint-Jacques, 75014 Paris, France.
| | - C Bottois
- Service de Pharmacie Clinique, hôpitaux universitaire Paris Centre-Site Cochin, 27, rue du Faubourg-Saint-Jacques, 75014 Paris, France
| | - S Dumas
- Service de Pharmacie Clinique, hôpitaux universitaire Paris Centre-Site Cochin, 27, rue du Faubourg-Saint-Jacques, 75014 Paris, France
| | - J Hubert
- Service de Pharmacie Clinique, hôpitaux universitaire Paris Centre-Site Cochin, 27, rue du Faubourg-Saint-Jacques, 75014 Paris, France
| | - A Molto
- Service de rhumatologie, Université Paris Descartes, Service de Rhumatologie B, Hôpital Cochin, AP-HP, Paris, France
| | - C Roux
- Service de rhumatologie, Université Paris Descartes, Service de Rhumatologie B, Hôpital Cochin, AP-HP, Paris, France
| | - M Dougados
- Service de rhumatologie, Université Paris Descartes, Service de Rhumatologie B, Hôpital Cochin, AP-HP, Paris, France
| | - O Conort
- Service de Pharmacie Clinique, hôpitaux universitaire Paris Centre-Site Cochin, 27, rue du Faubourg-Saint-Jacques, 75014 Paris, France
| |
Collapse
|
6
|
Waszczuk JR, Peacock L, Chadwick S, Maynard P, Raymond J, Roux C. Misidentifications of alphanumeric characters in serial number restorations. AUST J FORENSIC SCI 2022. [DOI: 10.1080/00450618.2022.2149855] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Affiliation(s)
- J. R Waszczuk
- Centre for Forensic Science, School of Mathematical and Physical Sciences, University of Technology Sydney, Ultimo, Australia
- Firearms Identification & Armoury Team, Australian Federal Police, Majura, Australia
| | - L. Peacock
- Centre for Forensic Science, School of Mathematical and Physical Sciences, University of Technology Sydney, Ultimo, Australia
| | - S. Chadwick
- Centre for Forensic Science, School of Mathematical and Physical Sciences, University of Technology Sydney, Ultimo, Australia
| | - P. Maynard
- Centre for Forensic Science, School of Mathematical and Physical Sciences, University of Technology Sydney, Ultimo, Australia
| | - J. Raymond
- Science and Research Unit, Forensic Evidence & Technical Services Command, New South Wales Police Force, Sydney, Australia
| | - C. Roux
- Centre for Forensic Science, School of Mathematical and Physical Sciences, University of Technology Sydney, Ultimo, Australia
| |
Collapse
|
7
|
Caroff A, Ramanah R, Nallet C, Pretalli JB, Roux C. [Embryo stage impact on the risk of ectopic pregnancy after In Vitro Fecondation]. Gynecol Obstet Fertil Senol 2022; 50:721-728. [PMID: 36055463 DOI: 10.1016/j.gofs.2022.08.004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/11/2022] [Revised: 07/31/2022] [Accepted: 08/03/2022] [Indexed: 06/15/2023]
Abstract
OBJECTIVES Ectopic pregnancies are still the first mortality cause of the first semestre of pregnancy. They are much more frequent in IVF (2-5%) than in the standard population (1-2%). The aim of this study was to compare the rate of ectopic pregnancies following a fresh embryo transfer done whether at an clived embryo stage (day 2 or 3 of the embryo development) or at a blastocyst stage (day 5 or 6 of the embryo development). METHODS This is a monocentric retrospective study including all 18 to 43 year-old patients getting pregnant (ßHCG>100 UI/L) after a fresh embryo transfer from In Vitro Fecondation with or without Intra-Cytoplasmic Sperm Injection, between January 1st 2014 and December 30th 2020 in the Hospital of Besançon (France). This population has been divided into 2 groups according to the embryo stage on the day of transfer. RESULTS Nine hundred and twenty two patients have been included. There were statistically more ectopic pregnancies after a blastocyst transfer (n=4; 5.4%) than after a clived embryo transfer (n=14; 1.7%). (P=0.049) CONCLUSION: In our population, there were more ectopic pregnancies from blastocyst(s) transfers than from clived embryo(es).
Collapse
Affiliation(s)
- A Caroff
- Service de gynécologie obstétrique, Centre Hospitalo-Universitaire Jean Minjoz, 3, boulevard Alexandre Flemming, 25000 Besançon, France.
| | - R Ramanah
- Service de gynécologie obstétrique, Centre Hospitalo-Universitaire Jean Minjoz, 3, boulevard Alexandre Flemming, 25000 Besançon, France
| | - C Nallet
- Service de gynécologie obstétrique, Centre Hospitalo-Universitaire Jean Minjoz, 3, boulevard Alexandre Flemming, 25000 Besançon, France
| | - J-B Pretalli
- Service de biologie de la reproduction, Centre Hospitalo-Universitaire Jean Minjoz, 3, boulevard Alexandre Flemming, 25000 Besançon, France
| | - C Roux
- Service de biologie de la reproduction, Centre Hospitalo-Universitaire Jean Minjoz, 3, boulevard Alexandre Flemming, 25000 Besançon, France
| |
Collapse
|
8
|
Launois R, Cabout E, Benamouzig D, Velpry L, Meto E, Briot K, Alliot F, Perrin L, Grange L, Sellami R, Touboul C, Joubert JM, Roux C. Freins et leviers de la mise en place d'une politique de prévention secondaire de l'ostéoporose : étude EFFEL. Rev Epidemiol Sante Publique 2022. [DOI: 10.1016/j.respe.2022.09.058] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
|
9
|
Villemur B, Roux C, Poggi JN, Elias A, Le Hello C. Is it justified to search for cancer in patients with peripheral arterial disease? J Med Vasc 2022; 47:133-140. [PMID: 36055682 DOI: 10.1016/j.jdmv.2022.07.003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/27/2022] [Accepted: 07/19/2022] [Indexed: 06/15/2023]
Abstract
BACKGROUND Cancer is the leading cause of death in European countries, ahead of cardiovascular diseases. Cancer is also the most common co-morbidity among patients hospitalized for the management of cardiovascular diseases. Through an overview, we searched for the frequency and types of cancer associated with peripheral arterial disease (PAD) in order to address the relevance of cancer screening in patients with PAD. METHODS We searched in PubMed database from 1996 to 2020 for retrospective and prospective cohort or cross-sectional or randomized studies evaluating the frequency of all types of cancer in patients with PAD excluding patients with aneurysmal disease. The keywords used were: peripheral arterial disease, arterial thrombosis, acute leg ischemia, critical leg ischemia, chronic leg ischemia, intermittent claudication, malignant tumor, cancer. RESULTS Based on published studies, the frequency of cancer in patients with PAD varied widely from 3.8 to 30.4% depending on study design, population, method used to screen for cancer and study period. In medical records database and registers,cancer prevalence varied from 3,8% to 22,4% in 4 retrospective studies of patients with acute limb ischemia and from 10.5 to 30.4% in 3 prospective studies of patients with acute limb ischemia, critical ischemia or intermittent claudication. In 3 retrospective analyses from 2 population-based cohorts and health insurance claims data, incidence of cancer in patients with intermittent claudication, acute limb ischemia or peripheral arterial disease varied from 8% to 11.7%. The frequency of cancer in PAD patients appeared higher than in the general population. Tobacco-dependent cancers seemed to be the most common cancers in PAD. Cancers were also more frequent in case of anemia, amputation and iterative bypass thrombosis in few studies. CONCLUSION Although there is no recommendation for cancer screening in patients with PAD, the high prevalence of cancer raises the question of screening patients at high risk such as those with acute or critical limb ischemia and especially in case of severe tobacco use, anemia, amputation and iterative bypass thrombosis. These results call for further studies with larger sample size and long term follow-up.
Collapse
Affiliation(s)
- B Villemur
- Unité et consultations de médecine vasculaire, CH Toulon, La Seyne sur mer, France.
| | - C Roux
- Clinique d'Alembert, Grenoble, France
| | - J-N Poggi
- Unité et consultations de médecine vasculaire, CH Toulon, La Seyne sur mer, France
| | - A Elias
- Unité et consultations de médecine vasculaire, CH Toulon, La Seyne sur mer, France
| | - C Le Hello
- CHU Saint-Étienne, Saint-Étienne, France
| |
Collapse
|
10
|
Rives A, Liard A, Bubenheim M, Barbotin A, Giscard D'Estaing S, Mirallié S, Ancelle A, Roux C, Brugnon F, Daudin M, Sibert L, Schneider P, Rives N. O-262 Impact of the cancer treatment received on the quality of the human (pre)pubertal testicular tissue prior to testicular tissue freezing (TTF). Hum Reprod 2022. [DOI: 10.1093/humrep/deac106.044] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Study question
What is the impact of the cancer treatment received prior to TTF and the disease on spermatogonia quantity in testicular tissue from (pre)pubertal boys?
Summary answer
A decrease in spermatogonia number was observed in testicular tissue after cancer treatment when cyclophosphamide equivalente dose (CED) is above 4000 mg/m2.
What is known already
The improved survival rates associated with the development of sperm and testicular tissue freezing (TTF) renders difficult not to offer fertility preservation to children or adolescents before cancer. Several studies exploring cancer patients have examined the number of spermatogonia per seminiferous tubular cross-section (S/T) or tubular fertility index (TFI, percentage of tubular cross-sections containing spermatogonia) in testicular biopsies. All studies, demonstrated that the S/T and TFI always decreased after the introduction of chemotherapy and more specifically in case of highly gonadotoxic risk such as alkylating agents.
Study design, size, duration
Testicular tissue samples from 79 (pre)pubertal boys diagnosed with cancer (ranging from 6 month to 16 years of age) were cryopreserved between May 2009 and June 2014. Medical diagnosis and previous chemotherapy exposure were recorded. We examined histological sections of (pre)pubertal testicular tissue to elucidate whether chemotherapy, doses or primary diagnosis affects the quality of testicular tissue.
Participants/materials, setting, methods
(Pre)pubertal boys with cancer diagnosis who benefitted from TTF prior to conditioning treatment for hematopoietic stem cell transplantation. All the patients included had previously received chemotherapy with moderate risk for future fertility. We have selected patients for whom data on chemotherapy received were complete. The quantity of spermatogonia and quality of testicular tissue were assessed by both morphological and immunohistochemical analysis.
Main results and the role of chance
The main finding was a significant reduction in spermatogonial cell counts in boys treated with alkylating agents. The mean S/T values in boys exposed to alkylating agents was significantly lower than in a group exposed to non-alkylating agents (p = 0.018). In contrast, no difference was observed for patients treated with carboplatin as the only alkylating agent compared to the group of patients exposed to non-alkylating agents. We observed an increase of S/T with age in the group of patients who did not receive alkylating agents and a decrease of S/T with age when patients received alkylating agents included in the CED formula (r = 0.6166, p = 0.0434; r= -0.3759, p = 0.0036, respectively). The TFI and S/T were decreased in the group of patients who received vincristine (p = 0.0049; p < 0.0001, respectively), but the CED was also significantly increased (p < 0.0001). Multivariate analysis, adjusted for CED, showed the persistence of a decrease in TFI correlated with vincristine administration (-0.5 [-0.96; 0.09], p = 0.02).
Limitations, reasons for caution
This is a descriptive study of testicular tissues obtained from patients who were at risk of infertility. Spermatognia functionanlity could not be tested by transplantation due limited sample size.
Wider implications of the findings
This study summarizes spermatogonia quantity and quality of testicular tissue of (pre)pubertal boys after potentially sterilizing treatments. We confirmed a negative correlation between the cumulative exposure to alkylating agents and the spermatogonial quantity. For patients in whom fertility preservation is indicated, TTF should be performed before initiation of alkylating agents.
Trial registration number
N/A
Collapse
Affiliation(s)
- A Rives
- Reproductive Biology Laboratory-CECOS- Rouen Normandie University Hospital , Normandie, Rouen, France
| | - A Liard
- Department of Child Surgery - Rouen Normandie University Hospital , Normandie, Rouen, France
| | - M Bubenheim
- DRCI- Rouen Normandie University Hospital , Normandie, Rouen, France
| | - A.L Barbotin
- Reproductive Biology Laboratory-CECOS- Lille University Hospital, Haut de France , Lille, France
| | - S Giscard D'Estaing
- Reproductive Biology Laboratory-CECOS- Lyon University Hospital , Rhone-Alpes , Lyon, France
| | - S Mirallié
- Reproductive Biology Laboratory-CECOS- Nantes University Hospital, Pays de la Loire , Nantes, France
| | - A Ancelle
- Reproductive Biology Laboratory-CECOS- Caen Normandie University Hospital , Normandie, Caen, France
| | - C Roux
- Reproductive Biology Laboratory-CECOS- Besançon University Hospital, Franche-Comté , Besançon, France
| | - F Brugnon
- Reproductive Biology Laboratory-CECOS- Clermont-Ferrand University Hospital , Auvergne, Clermont-Ferrand, France
| | - M Daudin
- Reproductive Biology Laboratory-CECOS- Toulouse University Hospital , Midi-pyrénées , Toulouse, France
| | - L Sibert
- Department of Urology and Andrology- Rouen Normandie University Hospital , Normandie, Rouen, France
| | - P Schneider
- Department of Pediatric Hematology and Oncology- Rouen Normandie University Hospital , Normandie, Rouen, France
| | - N Rives
- Reproductive Biology Laboratory-CECOS- Rouen Normandie University Hospital , Normandie, Rouen, France
| |
Collapse
|
11
|
Moltó A, Pinson P, Beeker N, Roux C. POS0196 NINE PERCENT OF PATIENTS PRESENT WITH MUSCULOSKELETAL SYMPTOMS AFTER A SEVERE SARS-CoV2 INFECTION: A DESCRIPTIVE ANALYSIS OF THE ASSISTANCE PUBLIQUE - HÔPITAUX DE PARIS CLINICAL DATA WAREHOUSE. Ann Rheum Dis 2022. [DOI: 10.1136/annrheumdis-2022-eular.1558] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
Backgroundthe main and most severe manifestation of the SARS-CoV2 infection is pneumonia, but other organ-specific symptoms have been described (myocarditis, encephalitis,..), and some sparse cases have reported musculoskeletal (MSK) symptoms following such an infection.Objectivesto determine the prevalence of MSK symptoms appearing after a SARS-CoV2 infection.Methodsthis was an observational cohort based on data available at the Assistance Publique-Hôpitaux de Paris (APHP) Clinical Data Warehouse (which includes data from patients admitted in the 39 APHP hospitals). Data collected included both ICD-10 codes in discharge summaries, and ‘key-words’ search on electronic medical records (EMR). To be included in the analysis, patients had to have a positive RT-PCR for SARS-CoV2 performed in APHP and be admitted in any APHP department between 1st March 2020 until 31st December 2020. Patients with past history of any MSK condition were excluded. MSK conditions were considered only if coded or reported in an EMR up to 90 days after the positive RT-PCR. Demographics and disease characteristics including treatment were compared in both groups (MSK yes/no) by T-test or ChiSquare test, accordingly.ResultsAmong the 55872 patients with a positive SARS-CoV2 RT-PCR performed in APHP, 17771 were admitted in APHP hospitals. Among them, 2170 had a previous history of MSK condition and were therefore excluded from this analysis. Among the remaining 15601 patients, 1370 (8.8%) presented with MSK symptoms. The most prevalent MSK symptoms were low back pain (32.9%), followed by joint pain (29.9%), radicular pain (20.2%) and joint effusion/arthritis (22.8%). Patients with MSK symptoms were older (67y vs. 64y, p<0.01), more frequently obese (29% vs. 25%, p=0.03), hypertensive (34% vs. 30%, p<0.01) and with diabetes (21% vs. 18%, p<0.01). There were no differences on gender nor on the ICU admission rate between groups (31% vs. 29%, NS); 30-days mortality was significantly lower in the MSK+ group probably due to selection bias (i.e. only patients who survived could present with MSK symptoms up to 90 days later) (7.8% vs. 16.9%, p<0.01). Treatment for SARS-CoV2 was slightly different in both groups, with higher corticosteroids (40.7% vs. 29.0%, p<0.01), antivirals (21.5% vs. 15.3%, p<0.01) and immunosuppressive drugs (8.5% vs. 4.5%, p<0.01) prescription rates in the MSK+ group.ConclusionMSK symptoms occurred in almost 9% of patients admitted to the hospital after a SARS-CoV2 infection, particularly in older and more comorbid patients. Further analysis evaluating the persistence of these symptoms are needed.AcknowledgementsWe would like to acknowledge all departments of Rheumatology of APHPDisclosure of InterestsAnna Moltó Consultant of: abbvie, MSD, BMS, Pfizer, Lilly, UCB, GIlead, Jansenn, NOvartis, Grant/research support from: UCB, Pierre Pinson: None declared, Nathanael Beeker: None declared, Christian Roux: None declared
Collapse
|
12
|
Labat G, Hayotte M, Brocq O, Bailly L, Fabre R, Fournier M, Breuil V, D’arripe Longueville F, Roux C. POS0953 IMPACT OF A WEARABLE ACTIVITY TRACKER ON DISEASE ACTIVITY IN SPONDYLOARTHRITIS: A RANDOMIZED CONTROLLED TRIAL. Ann Rheum Dis 2022. [DOI: 10.1136/annrheumdis-2022-eular.5189] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
BackgroundOther studies have shown the ability of a wearable activity tracker (TAP) to improve physical activity (PA) in different rheumatic diseases. Given the importance of PA in spondyloarthritis, our hypothesis is that the use of a TAP could improve physical activity and thus disease activity.ObjectivesThe purpose of this study is to evaluate the impact of a TAP used to encourage PA on disease activity in patients with spondyloarthritis.MethodsIn this randomized controlled trial consisting of three 12-week stages (Figure 1). Patients with spondyloarthritis were randomized to a group with TAP (GT), or a group without TAP (GST). For the first stage, both groups received physical activity counseling. In the second 12-week stage, no patients received TAP. In the third 12-week stage, all patients received supervised PA combined with TAP for GT only. Disease activity, performance (assessed by the TM6 6-minute walk test), and quality of life (assessed by the Short Form 36 Health Survey Questionnaire [SF-36]) were assessed at 12, 24, and 36 weeks. The primary endpoint was the progression of relapses between baseline and 12 weeks.Figure 1.ResultsA total of 108 patients were included in the study. At 12 weeks, both groups showed a non-significant improvement in the number of relapses: mean change (Δ), -0.32 [95% CI-0.68;60.09] in GT and Δ, -0.38 [95% CI-0.68;60.09] in GST. But, differences in outcome between groups were not significant (p=0.87). The TM6 was improved in the GT and GST groups at 12, 24, and 36 weeks (p < 0.01, and p < 0.001, respectively). We observed improvement in different dimensions of the SF36, mainly in physical function, emotional role, general health, and physical pain at 12 weeks (p < 0.01).Multivariate analysis showed improvement over time in performance (p < 0.01) and moderate flare-ups (p < 0.01) without the influence of a PAR (p = 0.29, and p = 0.66, respectively).ConclusionTo our knowledge, our study is the first to explore the impact of TAP use on disease activity in spondyloarthritis.We observed an improvement in disease activity, physical performance and quality of life without significant difference between the two groups. The lack of difference could be explained by the encouragement of physical activity to both groups. But also by the fact that our patients presented a significant number of severe relapses. Indeed, authors have shown the limits of the use of TAP in severe diseases, particularly in pulmonary pathologies [1].Our study did not show any effect of the use of a connected object on disease activity. However, this study confirmed the benefits of physical activity on disease activity, quality of life and physical performance in patients with spondyloarthritis.References[1]Bentley CL, Powell L, Potter S, et al. The use of a smartphone app and an activity tracker to promote physical activity in the management of chronic obstructive pulmonary disease: randomized controlled feasibility study. J.M.I.R. MHealth UHealth 2020;8:e16203. https://doi.org/10.2196/16203.Disclosure of InterestsGuillaume Labat: None declared, Meggy Hayotte: None declared, Olilvier Brocq: None declared, laurent bailly: None declared, Roxane fabre: None declared, manuella Fournier: None declared, Véronique Breuil: None declared, fabienne d’arripe longueville: None declared, Christian Roux Speakers bureau: Pfizer, BMS, Novartis, Lilly, Grant/research support from: Novartis and Lilly
Collapse
|
13
|
Amigues C, Fresse A, Roux C, Gauthier S, Vieillard MH, Drici MD, Breuil V. OP0240 ZOLEDRONATE-RELATED OSTEONECROSIS OF THE JAW IN OSTEOPOROSIS: INCIDENCE, RISK FACTORS AND COMPARISON TO ORAL BISPHOSPHONATES. Ann Rheum Dis 2022. [DOI: 10.1136/annrheumdis-2022-eular.2876] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
BackgroundMediatization of bisphosphonate(BP)-related osteonecrosis of the jaw (ONJ) has hampered the treatment of osteoporosis (OP). The risk of ONJ associated with oral BP in OP and zoledronate (ZOL) in oncology has previously been reported. However, the risk of ZOL-related ONJ in OP has only been reported in Randomized clinical trials.ObjectivesTherefore, we aimed to characterize ZOL-related ONJ in OP and compare it’s incidence with oral BP in real life setting.MethodsAll reports of adverse events (AEs) of BP (ZOL, alendronate (ALN), risedronate (RIS)) were extracted from the French pharmacovigilance database (FPD) since its origin till 2020. For ZOL, cases were separated by indication, rheumatological (ZOL-R) or oncological (ZOL-K). The risk factors analyzed for ONJ were age, sex, active smoking, alcoholism, diabetes, corticotherapy, neoplasia, previous treatment by chemo or immunotherapy, recent dental care and time of exposure to BP. The association between the occurrence of ONJ and the associated BP was assessed by calculating the reporting odds ratio (ROR) in a case/non-case study. Stratification on assumed risk factors was performed to assess their impact on the risk of ONJ.The incidence of ONJ under BP between 2011 and 2020 was estimated by relating the number of ONJ cases under BP reported to the FPD to the estimated number of patients treated with ZOL, ALN and RIS over the same period according to health insurance reimbursement data of Medic AM database. Incidence rate calculation, confidence interval calculation, and comparison of incidence rates (Fischer exact test) were performed.ResultsFor ZOL 2254 AEs were reported: 568 ONJ/1103 AES with ZOL-K and 70 ONJ/1151 AEs with ZOL-R. For ZOL-R-related ONJ, 30/70 cases had recent dental care and 48.7 months of mean time of exposure to BP. Risk factors for ONJ were smoking, history of neoplasia and chemotherapy. For ALN, 1,010 AEs were reported, including 188 ONJ. 91/188 ONJ had recent dental care and 70.9 months of mean time of exposure to BP. Risk factors for ONJ were age ≥65 years, diabetes, corticotherapy, and history of neoplasia. For RIS, 771 AEs were reported including 68 cases of ONJ. 28/68 ONJ had recent dental care and 53.6 months the average time of exposure to BP. The risk factors were age ≥ 65 years, smoking, corticotherapy, history of neoplasia and chemotherapy. ROR calculation shows that corticotherapy was associated more frequently with RIS (2.10 [1.64-2.69]) and ALN (1.33 [1.04-1.70]) as compared with ZOL-R, with no other significant difference.The incidence of ONJ was significantly higher with ZOL-R than with RIS (p<0.001) and ALN (p<0.001). Indeed, between 2011 and 2020, 614 932 patients were treated with ZOL-R and 59 cases of ONJ reported yielding an incidence of 9.6/100,000 person-years; 2 233 536 patients were treated with RIS and 44 cases of ONJ reported yielding an incidence of 2.0/100 000 person-years; 2 432 373 patients were treated with ALN and 125 cases of ONJ reported yielding an incidence of 5.1/100 000 person-years.ConclusionOur data confirm in real-life settings and a large population, that BP-related ONJ is a rare event associated with OP. The risk of BP-related ONJ appears related to the potency of bone resorption inhibition, as RIS has the lowest and ZOL-R the highest risk. Smoking appears a consistent risk factor of ONJ, as is recent dental care. However, we must stress out the usual limitations of pharmacovigilance studies, their retrospective nature, common under-reporting of adverse-events, and the fact that the Medic AM database only refers to city reimbursements.To our knowledge, this is the first study reporting the risk of ONJ under ZOL from the national pharmacovigilance database. Our study confirms the rarity, in OP, of BP-related ONJ. The risk of incidence of ONJ on ZOL-R is higher than on RIS and ALN, suggesting a risk associated with the inhibitory power of bone resorption.AcknowledgementsAcknowledgements to the French Network of Pharmacovigilance CentersDisclosure of InterestsClaire Amigues: None declared, Audrey Fresse: None declared, Christian Roux: None declared, Sophie Gauthier: None declared, Marie-Hélène Vieillard: None declared, Milou-Daniel Drici: None declared, Véronique Breuil Speakers bureau: AMGEN MSD UCB THERAMEX LILLY, Consultant of: AMGEN MSD UCB THERAMEX LILLY, Grant/research support from: AMGEN LILLY
Collapse
|
14
|
Beaudart C, Boonen A, Li N, Bours S, Goemaere S, Reginster JY, Roux C, McGowan B, Diez-Perez A, Rizzoli R, Cooper C, Hiligsmann M. Patient preferences for lifestyle behaviours in osteoporotic fracture prevention: a cross-European discrete choice experiment. Osteoporos Int 2022; 33:1335-1346. [PMID: 35080632 PMCID: PMC9106627 DOI: 10.1007/s00198-022-06310-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/15/2021] [Accepted: 01/12/2022] [Indexed: 11/26/2022]
Abstract
UNLABELLED Using a discrete choice experiment, we aimed to assess patients' preferences with regard to adopting lifestyle behaviours to prevent osteoporotic fractures. Overall, the 1042 patients recruited from seven European countries were favourable to some lifestyle behaviours (i.e., engaging in moderate physical activity, taking calcium and vitamin D supplements, reducing their alcohol consumption and ensuring a normal body weight). INTRODUCTION Alongside medical therapy, healthy lifestyle habits are recommended for preventing osteoporotic fractures. In this study, we aimed to assess patients' preferences with regard to adopting lifestyle changes to prevent osteoporotic fractures. METHODS A discrete choice experiment was conducted in seven European countries. Patients with or at risk of osteoporosis were asked to indicate to what extent they would be motivated to adhere to 16 lifestyle packages that differed in various levels of 6 attributes. The attributes and levels proposed were physical activity (levels: not included, moderate or high), calcium and vitamin D status (levels: not included, taking supplements, improving nutrition and assuring a minimal exposure to sunlight daily), smoking (levels: not included, quit smoking), alcohol (levels: not included, moderate consumption), weight reduction (levels: not included, ensure a healthy body weight) and fall prevention (levels: not included, receiving general advice or following a 1-day fall prevention program). A conditional logit model was used to estimate a patient's relative preferences for the various attributes across all participants and per country. RESULTS In total, 1042 patients completed the questionnaire. Overall, patients were favourable to lifestyle behaviours for preventing osteoporotic fractures. However, among the lifestyle behaviours proposed, patients were consensually not prone to engage in a high level of physical activity. In addition, in Ireland, Belgium, the Netherlands and Switzerland, patients were also not inclined to participate in a 1-day fall prevention program and Belgian, Swiss and Dutch patients were not prone to adhere to a well-balanced nutritional program. Nevertheless, we observed globally that patients felt positively about reducing their alcohol consumption, engaging in moderate physical activity, taking calcium and vitamin D supplements and ensuring a normal body weight, all measures aimed at preventing fractures. CONCLUSIONS In a patient-centred approach, fracture prevention should take these considerations and preferences into account.
Collapse
Affiliation(s)
- C Beaudart
- Department of Health Services Research, CAPHRI Care and Public Health Research Institute, Maastricht University, Maastricht, the Netherlands.
| | - A Boonen
- Division of Rheumatology, Department of Internal Medicine, and CAPRHI Care and Public Health Research Institute, Maastricht University Medical Center, Maastricht, the Netherlands
| | - N Li
- Department of Health Services Research, CAPHRI Care and Public Health Research Institute, Maastricht University, Maastricht, the Netherlands
| | - S Bours
- Department of Health Services Research, CAPHRI Care and Public Health Research Institute, Maastricht University, Maastricht, the Netherlands
| | - S Goemaere
- Department of Rheumatology and Endocrinology, Ghent University Hospital, Ghent, Belgium
| | - J-Y Reginster
- WHO Collaborating Center for Public Health Aspects of Musculo-Skeletal Health and Ageing, Division of Public Health, Epidemiology and Health Economics, University of Liège, Liège, Belgium
| | - C Roux
- Department of Rheumatology, Paris Descartes University, Paris, France
| | - B McGowan
- The North Western Rheumatology Unit, Our Lady's Hospital, Manorhamilton, Co. Leitrim, Ireland
| | - A Diez-Perez
- Musculoskeletal Research Unit (IMIM) and CIBERFES, Universitat Autònoma de Barcelona, Barcelona, Spain
| | - R Rizzoli
- Division of Bone Diseases, Geneva University Hospitals and Faculty of Medicine, Geneva, Switzerland
| | - C Cooper
- MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton General Hospital, Southampton, UK
| | - M Hiligsmann
- Department of Health Services Research, CAPHRI Care and Public Health Research Institute, Maastricht University, Maastricht, the Netherlands
| |
Collapse
|
15
|
Paccou J, Javier RM, Henry-Desailly I, Ternynck C, Nottez A, Legroux-Gérot I, Robin F, Fardellone P, Lespessailles E, Roux C, Guggenbuhl P, Kolta S, Cortet B. The French multicentre elevated bone mass study: prevalence and causes. Osteoporos Int 2021; 32:1763-1775. [PMID: 33655400 DOI: 10.1007/s00198-021-05898-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/11/2020] [Accepted: 02/16/2021] [Indexed: 10/22/2022]
Abstract
UNLABELLED The purpose of this multicentric study was to evaluate the prevalence and causes of Elevated Bone Mass (EBM) in patients who underwent DXA scanning over a 10-year period. The prevalence of EBM was 1 in 100. The main causes of EBM were degenerative spine disorders and renal osteodystrophy. INTRODUCTION Reports of elevated bone mass (EBM) on routine dual energy X-Ray absorptiometry (DXA) scanning are not infrequent. However, epidemiological studies of EBM are few and definition thresholds are variable. The purpose of this French multicentric study was to evaluate the prevalence and causes of EBM in adult patients who underwent DXA scanning over a 10-year period. METHODS This multicentric, retrospective study was conducted in six French regional bone centres. DXA databases were initially searched for individuals with a bone mineral density (BMD) Z-score ≥ +4 at any site in the lumbar spine or hip from April 1st, 2008 to April 30st, 2018. RESULTS In all, 72,225 patients with at least one DXA scan were identified. Of these, 909 (322 men and 587 women) had a Z-score ≥ + 4, i.e. a prevalence of 1.26% [1.18-1.34%]. The DXA scan reports and imagery and medical records of the 909 EBM patients were reviewed and 936 causes were found. In 42 patients (4%), no cause could be determined due to unavailability of data. Artefactual causes of EBM were found in 752 patients (80%), in whom the predominant cause was degenerative disease of the spine (613 patients, 65%). Acquired causes of focal EBM-including Paget's disease (n = 7)-were found in 12 patients (1%), and acquired causes of generalized EBM-including renal osteodystrophy (n = 32), haematological disorders (n = 20) and hypoparathyroidism (n = 15)-in 84 patients (9%). Other causes were rare hereditary diseases and unknown EBM in 19 (2%) and 27 (3%) cases respectively. CONCLUSIONS The prevalence of EBM was approximately 1 in 100. These findings suggest that degenerative disease of the spine is the main cause of EBM, but that acquired or hereditary diseases are also causal factors.
Collapse
Affiliation(s)
- J Paccou
- Rheumatology Unit, MABlab ULR 4490, Lille University Hospital, CHRU Lille, rue Emile Laine, 59037, Lille, France.
| | - R-M Javier
- Rheumatology Unit, Strasbourg University Hospital, Strasbourg, France
| | - I Henry-Desailly
- Rheumatology Unit, Picardie-Jules Verne University, Amiens Teaching Hospital, Amiens, France
| | - C Ternynck
- Lille University Hospital, CHRU Lille, ULR 2694-METRICS, F-59037, Lille, France
| | - A Nottez
- Rheumatology Unit, Lille University Hospital, CHRU Lille, 59037, Lille, France
| | - I Legroux-Gérot
- Rheumatology Unit, MABlab ULR 4490, Lille University Hospital, CHRU Lille, rue Emile Laine, 59037, Lille, France
| | - F Robin
- Rheumatology Unit, CHU de Rennes, Univ Rennes, INSERM, INRA, Institut NUMECAN (Nutrition Metabolisms and Cancer), UMR 1241, F-35000, Rennes, France
| | - P Fardellone
- Rheumatology Unit, Picardie-Jules Verne University, Amiens Teaching Hospital, Amiens, France
| | - E Lespessailles
- Rheumatology Unit, Regional Hospital of Orleans, EA 4708-I3MTO, University of Orleans, Orleans, France
| | - C Roux
- Rheumatology Unit, INSERM U1153 APHP Centre, Université de Paris, Paris, France
| | - P Guggenbuhl
- Rheumatology Unit, CHU de Rennes, Univ Rennes, INSERM, INRA, Institut NUMECAN (Nutrition Metabolisms and Cancer), UMR 1241, F-35000, Rennes, France
| | - S Kolta
- Rheumatology Unit, INSERM U1153 APHP Centre, Université de Paris, Paris, France
| | - B Cortet
- Rheumatology Unit, MABlab ULR 4490, Lille University Hospital, CHRU Lille, rue Emile Laine, 59037, Lille, France
| |
Collapse
|
16
|
Zver T, Frontczak S, Berdin A, Amiot C, Roux C. P–436 Identification of ovarian cell subpopulations by multicolor flow cytometry and its potential impact on ovarian reconstruction programs. Hum Reprod 2021. [DOI: 10.1093/humrep/deab130.435] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Study question
How could multicolor flow cytometry (MFC) help to identify ovarian subpopulations that could be used for ovarian reconstruction with isolated follicles?
Summary answer
MFC is useful to identify ovarian cell subpopulations in the ovarian cortex.
What is known already
Ovarian tissue cryopreservation is a fertility preservation option for women before gonadotoxic chemo- and/or radiotherapy. However, graft of cryopreserved ovarian tissue must be performed with caution in women suffering from malignancies that may metastasize to the ovaries. For this purpose, functional ovarian tissue qualification is essential to identify ovarian cell subpopulations that could be used for ovary reconstruction in combination with isolated follicles. Furthermore, ischemic tissue damage occurring after the graft is currently another important issue to be resolved for successful ovarian reuse.
Study design, size, duration
We developed an automated ovarian tissue dissociation method to obtain ovarian cell suspensions. Then, we used MFC for the identification of different cell subpopulations in the cell suspension thus obtained.
Participants/materials, setting, methods
Human ovarian tissues from patients undergoing surgery for polycystic ovary syndrome were used in this study. Biopsies of ovarian cortex (fresh or frozen-thawed) were dissociated using an automated dissociation method.
We used FVS780 and SYTO13 markers to gate viable ovarian cells by MFC. Variable markers were chosen to differentiate and identify cell subpopulations among the viable ovarian cells.
Main results and the role of chance
The dissociation yield was on average 1.59 ± 1.58 x 106 and 0.78 ± 0.72 x 106 viable ovarian cells per 100 mg of fresh (n = 17) and frozen-thawed (n = 43) ovarian cortical tissue, respectively. On average, 35.4 ± 13.1% of viable ovarian cells were CD34 + (n = 61, stromal phenotype). Concerning endothelial phenotype, 7.8 ± 5.5% of CD31+ cells (n = 51) and 5.3 ± 3.6% of CD144+ cells (n = 29) were identified among viable ovarian cells. Vimentin marker is found in 25.6 ± 10.8% of viable ovarian cells (n = 23) and CD326 (EpCAM expression) in 0.6 ± 0.8% (n = 16). Finally, pericyte phenotype (CD34-/Vimentin-/CD31-/CD146+/ CD140b+) was identified in 4.6 ± 4.3% of viable ovarian cells (n = 7).
Limitations, reasons for caution
We do not know how these ovarian cell subpopulations could be a factor associated or not with time for ovarian function recovery in vivo after ovarian tissue graft and the impact of these ovarian cells on the ovarian microenvironment of an artificial ovary.
Wider implications of the findings: Functional qualification of ovarian tissue can be performed by MFC. MFC is a promising tool for ovarian cortex qualification before reuse of cryopreserved ovarian tissue. Cell sorting could be used to separate and isolate cell subpopulations and add these cells with isolated follicles in an ovarian reconstruction program.
Trial registration number
Not applicable
Collapse
Affiliation(s)
- T Zver
- CHU de Besançon, Service de Biologie et Médecine de la Reproduction- Cryobiologie - CECOS, F–25000 Besançon, France
- CHU de Besançon, INSERM CIC–1431- Centre d’Investigation Clinique en Biothérapies, F–25000 Besançon, France
- Université Bourgogne Franche-Comté, INSERM- EFS BFC- UMR1098- Interactions Hôte-Greffon-Tumeur/Ingénierie Cellulaire et Génique, F–25000 Besançon, France
| | - S Frontczak
- CHU de Besançon, Service de Biologie et Médecine de la Reproduction- Cryobiologie - CECOS, F–25000 Besançon, France
- CHU de Besançon, INSERM CIC–1431- Centre d’Investigation Clinique en Biothérapies, F–25000 Besançon, France
- Université Bourgogne Franche-Comté, INSERM- EFS BFC- UMR1098- Interactions Hôte-Greffon-Tumeur/Ingénierie Cellulaire et Génique, F–25000 Besançon, France
| | - A Berdin
- CHU de Besançon, Service de Gynécologie Obstétrique, F–25000 Besançon, France
| | - C Amiot
- CHU de Besançon, Service de Biologie et Médecine de la Reproduction- Cryobiologie - CECOS, F–25000 Besançon, France
- CHU de Besançon, INSERM CIC–1431- Centre d’Investigation Clinique en Biothérapies, F–25000 Besançon, France
- Université Bourgogne Franche-Comté, INSERM- EFS BFC- UMR1098- Interactions Hôte-Greffon-Tumeur/Ingénierie Cellulaire et Génique, F–25000 Besançon, France
| | - C Roux
- CHU de Besançon, Service de Biologie et Médecine de la Reproduction- Cryobiologie - CECOS, F–25000 Besançon, France
- CHU de Besançon, INSERM CIC–1431- Centre d’Investigation Clinique en Biothérapies, F–25000 Besançon, France
- Université Bourgogne Franche-Comté, INSERM- EFS BFC- UMR1098- Interactions Hôte-Greffon-Tumeur/Ingénierie Cellulaire et Génique, F–25000 Besançon, France
| |
Collapse
|
17
|
Herrou J, Godart N, Etcheto A, Kolta S, Barthe N, Maugars AY, Thomas T, Roux C, Briot K. Absence of relationships between depression and anxiety and bone mineral density in patients hospitalized for severe anorexia nervosa. Eat Weight Disord 2021; 26:1975-1984. [PMID: 33085062 DOI: 10.1007/s40519-020-01045-9] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/03/2020] [Accepted: 10/03/2020] [Indexed: 11/27/2022] Open
Abstract
INTRODUCTION Low BMD is frequent in anorexia nervosa (AN), depression, and during SSRI treatment but relation between these elements in AN is not established. The aims of this study were to assess the relationships between depression and anxiety, SSRI prescription, and (1) low BMD during inpatient treatment and (2) BMD change 1 year after hospital discharge. METHODS From 2009 to 2011, 212 women with severe AN have been included in the EVHAN study (EValuation of Hospitalisation for AN). Depression, anxiety and obsessive-compulsive symptoms and comorbidity were evaluated using psychometric scales and CIDI-SF. BMD was measured by dual-energy X-ray absorptiometry. RESULTS According to the CIDI-SF, 56% of participants (n = 70) had a lifetime major depressive disorder, 27.2% (n = 34) had a lifetime obsessive-compulsive disorder, 32.8% (n = 41) had a lifetime generalized anxiety disorder and 25.6% (n = 32) had a lifetime social phobia disorder. Half of the sample (50.7%; n = 72) had a low BMD (Z score ≤ - 2). In multivariate analysis, lifetime lowest BMI was the only determinant significantly associated with low BMD (OR = 0.56, p = 0.0008) during hospitalization. A long duration of AN (OR = 1.40 (0.003-3.92), p = 0.03), the AN-R subtype (OR = 4.95 (1.11-26.82), p = 0.04), an increase of BMI between the admission and 1 year (OR = 1.69 (1.21-2.60), p = 0.005) and a gain of BMD 1 year after the discharge explained BMD change. CONCLUSION We did not find any association between depression and anxiety or SSRI treatment and a low BMD or variation of BMD. LEVEL OF EVIDENCE Level III, cohort study.
Collapse
Affiliation(s)
- J Herrou
- INSERM UMR-1153, Paris, France.
- Department of Rheumatology, Cochin Hospital, 75014, Paris, France.
| | - N Godart
- Fondation de Santé des Etudiants de France (FSEF), Paris, France
- UFR des Sciences de la Santé Simone Veil (UVSQ), Versailles, France
- CESP, INSERM, UMR 1018, Université Paris-Sud, UVSQ, Université Paris-Saclay, Villejuif, France
| | - A Etcheto
- Université Paris Descartes, Faculté de Médecine Paris Descartes, 75014, Paris, France
| | - S Kolta
- INSERM UMR-1153, Paris, France
| | - N Barthe
- Department of Nuclear Medicine, CHU Bordeaux, Bordeaux, France
| | - A Y Maugars
- Department of Rheumatology, CHU Nantes, Nantes, France
| | - T Thomas
- Department of Rheumatology, Hospital Nord, CHU de Saint Etienne, INSERM 1059, Lyon University, Lyon, France
| | - C Roux
- INSERM UMR-1153, Paris, France
- Université Paris Descartes, Faculté de Médecine Paris Descartes, 75014, Paris, France
| | - K Briot
- INSERM UMR-1153, Paris, France
- Université Paris Descartes, Faculté de Médecine Paris Descartes, 75014, Paris, France
| |
Collapse
|
18
|
Pithois A, Mauppin C, Decaigny P, Tio G, Berdin A, Roux C, Pretalli JB. [Overweight or obesity: impact on the results of the first IVF/ICSI attempt]. Gynecol Obstet Fertil Senol 2021; 49:593-600. [PMID: 33484901 DOI: 10.1016/j.gofs.2021.01.012] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/02/2020] [Indexed: 06/12/2023]
Abstract
OBJECTIVES To evaluate the influence of overweight and obesity on the results of the first in vitro fertilization attempt, without or with intracytoplasmic microinjection (IVF/ICSI), in terms of live births. METHODS Retrospective observational study concerning the first IVF/ICSI attempts from 01/01/2006 to 31/12/2017 carried out at the Assisted Reproductive Technology of the CHU of Besançon, studying the delivery rate (excluding frozen embryos transfers), and the data of Assisted Reproductive Technology attempts, in overweight (BMI 25 to 29.9kg/m2) and obese women (BMI≥30kg/m2), compared to women with a standard BMI (18 to 24.9kg/m2). RESULTS A total of 3192 patients were included. At the end of their first IVF/ICSI attempt, the delivery rate of women with standard BMI was 34.7%. The delivery rate was significantly lower in overweight women (29.5%, p=0.011) and comparable in obese women (32.4%, p=0.476). The birth rate of women with a BMI≥25 kg/m2 was also significantly lower than that of women with a standard BMI (30.4% versus 34.7%, p=0.019). After multivariate analysis, the delivery rate in overweight patients remained significantly lower compared to the population with standard BMI (OR=0.707; 95% CI 0.561-0.890), and comparable in obese patients (OR=0.796; 95% CI 0.585-1.084). CONCLUSION The delivery rate was lower in overweight women, whereas it was not significantly different in obese women.
Collapse
Affiliation(s)
- A Pithois
- Centre d'AMP, CHU Besançon, 25000 Besançon, France.
| | - C Mauppin
- Centre d'AMP, CHU Besançon, 25000 Besançon, France
| | - P Decaigny
- Centre d'AMP, CHU Besançon, 25000 Besançon, France
| | - G Tio
- Inserm CIC 1431, CHU Besançon, 25000 Besançon, France
| | - A Berdin
- Centre d'AMP, CHU Besançon, 25000 Besançon, France
| | - C Roux
- Centre d'AMP, CHU Besançon, 25000 Besançon, France; Inserm CIC 1431, CHU Besançon, 25000 Besançon, France
| | - J-B Pretalli
- Centre d'AMP, CHU Besançon, 25000 Besançon, France; Inserm CIC 1431, CHU Besançon, 25000 Besançon, France
| |
Collapse
|
19
|
Levy A, Roux C, Mercier O, Issard J, Botticella A, Barlesi F, Le Péchoux C. [Radiotherapy for oligometastatic non-small cell lung cancer patients]. Cancer Radiother 2021; 25:517-522. [PMID: 34175225 DOI: 10.1016/j.canrad.2021.06.011] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/31/2021] [Accepted: 06/05/2021] [Indexed: 10/21/2022]
Abstract
The oligometastatic disease concept suggests that patients with a limited number of metastases have a favorable prognosis. Radical local treatment of oligometastatic patients has then increased given developments in imaging (mainly positron emission tomography and brain magnetic resonance imaging) and access to effective and better tolerated treatments. Stereotactic radiotherapy has the advantage of being noninvasive, allowing a good rate of local control and a limited number of side effects. A better definition of oligometastatic disease, particularly for non-small cell lung cancer (NSCLC), has recently been published. For patients with NSCLC, two randomized phase II trials also suggested that the addition of a radical local treatment results in encouraging survival data, with a good safety profile. A single-arm phase II finally showed a benefit when combining a radical local treatment with an anti-PD1 immunotherapy. This review describes the definitions of oligometastatic disease, the main prospective findings including radiation therapy, and prospects for oligometastatic NSCLC patients.
Collapse
Affiliation(s)
- A Levy
- Gustave-Roussy, département d'oncologie radiothérapie, 94805 Villejuif, France; Centre international des cancers thoraciques (CICT), Gustave-Roussy, 94805 Villejuif, France; Université Paris-Saclay, Inserm U1030, radiothérapie moléculaire, 94805 Villejuif, France; Université Paris-Saclay, faculté de médecine, 94270 Le Kremlin-Bicêtre, France.
| | - C Roux
- Centre international des cancers thoraciques (CICT), Gustave-Roussy, 94805 Villejuif, France; Département de radiologie, Gustave-Roussy, 94805 Villejuif, France
| | - O Mercier
- Centre international des cancers thoraciques (CICT), Gustave-Roussy, 94805 Villejuif, France; Université Paris-Saclay, faculté de médecine, 94270 Le Kremlin-Bicêtre, France; Département de chirurgie thoracique et vasculaire et transplantation cardiopulmonaire, groupe hospitalier Paris Saint-Joseph-Marie-Lannelongue, 92350 Le Plessis-Robinson, France
| | - J Issard
- Centre international des cancers thoraciques (CICT), Gustave-Roussy, 94805 Villejuif, France; Département de chirurgie thoracique et vasculaire et transplantation cardiopulmonaire, groupe hospitalier Paris Saint-Joseph-Marie-Lannelongue, 92350 Le Plessis-Robinson, France
| | - A Botticella
- Gustave-Roussy, département d'oncologie radiothérapie, 94805 Villejuif, France; Centre international des cancers thoraciques (CICT), Gustave-Roussy, 94805 Villejuif, France
| | - F Barlesi
- Centre international des cancers thoraciques (CICT), Gustave-Roussy, 94805 Villejuif, France; Gustave-Roussy Cancer Campus, Villejuif, France; Aix-Marseille université, Inserm, CNRS, CRCM, Marseille, France
| | - C Le Péchoux
- Gustave-Roussy, département d'oncologie radiothérapie, 94805 Villejuif, France; Centre international des cancers thoraciques (CICT), Gustave-Roussy, 94805 Villejuif, France
| |
Collapse
|
20
|
Assaraf M, Chevet B, Philippe P, Avouac J, Delacour M, Houvenagel E, Pascart T, Henry J, Roux C, Wendling D, Paccou J, Cortet B, Devauchelle-Pensec V, Flipo RM. POS0818 TREATMENT OF POLYMYALGIA RHEUMATICA WITH TOCILIZUMAB: RESULTS OF AN OBSERVATIONAL RETROSPECTIVE MULTICENTER STUDY. Ann Rheum Dis 2021. [DOI: 10.1136/annrheumdis-2021-eular.3885] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
Background:In 2017, TOCILIZUMAB (TCZ) obtained marketing authorization for treatment of giant cell arteritis (GCA); however, this doesn’t extend to polymyalgia rheumatica (PMR) therapy. Based on efficacy data for TCZ in GCA, TCZ is sometimes used as a glucocorticoid (GC) sparing agent when PMR is GC dependent or when a rapid steroid withdraw is needed. Currently, there are no available recommendations on the use of this therapeutic class in for this particular indication.Objectives:Here, we present the results of an observational French multicentric study of patients with PMR treated with TCZ.Methods:Thirteen medical centers were included in this study. The data was collected retrospectively between 2015 and 2020. The minimum duration of treatment was 3 months. Patients were included when receiving TCZ for isolated PMR or associated with a non-active GCA (asymptomatic, no vascular fixation on PET scanner).Results:Overall, 34 patients were included (24 women; mean age 70.1 years (+/-10.3)). At TCZ introduction, patients had been treated with GC for a mean duration of 27,9 months (+/-25.9) and the mean GC dose was 16,8mg/d (+/-10). Fifteen patients (44%) had one or more complications from GC therapy. Another immunosuppressant was added before TCZ treatment for 25 (74%); mostly METHOTREXATE (24/25).TCZ was initiated intravenously at 8mg/kg every 4 weeks for 27 patients (79%) and subcutaneously at 162mg/week for 7 patients (21%).The reasons for TCZ introduction included GC dependence (n=30, 88%), and necessity of quick GC sparing (n=4 patients,12%).Of all patients, 76% (26 patients) had stopped GC treatment definitively, with a mean time of 9,4 (0-32) months.The mean TCZ treatment period was 19,2 months (3-66). Fifteen patients (44%) permanently stopped TCZ at the end of the observation period (8 prolonged remissions;1 myocardial infarction; 1 cutaneous lymphoma; 1 primary failure, 3 lost to follow up).Eighteen patients (60%) benefited from an attempted tapering of TCZ (infusion spacing or dose reduction), 6 attempts (1/3) led to a relapse. 1/2 patients had side effects mostly benign (cytopenia n=6, infections n=5).Conclusion:This is the largest cohort presenting results of the use of TCZ in PMR. Despite the small number of participants, our study suggests TCZ is effective as a GC sparing agent in PMR. As there are no official recommendations of use, indications for TCZ use within this population are no defined. Randomized Controlled Trial would be beneficial to validate these first results.References:[1]Toussirot, « Biothérapies, pseudo- polyarthrite rhizomélique et artérite à cellules géantes État des lieux en 2018 ».[2]Devauchelle-Pensec et al., « Efficacy of First-Line Tocilizumab Therapy in Early Polymyalgia Rheumatica ».[3]Genovese et al., « Longterm Safety and Efficacy of Tocilizumab in Patients with Rheumatoid Arthritis ».[4]Stone et al., « Trial of Tocilizumab in Giant-Cell Arteritis ».Disclosure of Interests:None declared
Collapse
|
21
|
Trojani MC, Bendahan D, Chorin F, Gerus P, Breuil V, Guis S, Roux C. POS0284 CLINICAL AND MRI COMPARISON OF ECCENTRIC VERSUS CONCENTRIC REHABILITATION IN SYMPTOMATIC KNEE OSTEOARTHRITIS: A PROSPECTIVE RANDOMIZED STUDY. Ann Rheum Dis 2021. [DOI: 10.1136/annrheumdis-2021-eular.3164] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
Background:Rehabilitation is at the center of the non-medical management of knee osteoarthritis. Concentric muscle strengthening is often preferred, while eccentric contractions play an important role in controlling knee flexion and knee stability and allow the development of a high level of strength with a low energy cost. But few studies have focused on these two techniqueObjectives:To explore the effect of a 6-week-exercise program on function, pain and performance level in symptomatic knee osteoarthritis patientsMethods:An analysis was performed of the data from 60 individuals with symptomatic knee osteoarthritis who were included in the EXART study. The EXART study was a prospective, randomized controlled trial which included patients aged 40 to 85 with KL 2 or 3 responding to the American College of Rheumatology criteria. The first group benefitted from a 6 week eccentric rehabilitation program and the second group from a standard 6 week concentric rehabilitation program. The endpoints were the changes from baseline to week 6 in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC), pain, and performance measured with quadriceps power (PMax) and contraction strength (MMax). MRI muscle analysis was performed before and after physical activity.Results:Among 80 patients screened, 60 were included in the study and randomized. 25/30 subjects finished the program in the concentric group and 28/30 in the eccentric group. The mean population age was 74 (+/-8), mean IMC 27.2 (+/-4). The baseline total WOMAC mean was 49.2 (+/-19), VAS pain 5.3 (+/-2). At 6 weeks, both groups showed a significant improvement compared to baseline for the WOMAC without any difference between the two groups (mean difference evolution concentric = 7.5 ± 11.9 (p= p<0.0001); mean difference evolution eccentric = 4.5 ± 1.9 (p<0.0001); intergroup analysis p=0.7). Similar significant results were found in the WOMAC function subscale. No difference between the groups appeared in VAS pain evolution (p= 0.7). The eccentric group showed a significant improvement in PMax and high speed MMax evolution (p=0.001 and p=0.002). This improvement was not found for the concentric group (p= 0.52 and p=0.27). MRI showed a vastus medialis hypertrophy only in the eccentric group (p=0.002). We did not observe any change in the fatty infiltration of the quadriceps on MRI.Conclusion:Rehabilitation, whether eccentric or concentric, has a beneficial action on function and pain in symptomatic knee osteoarthritis whatever the methods. A gain in muscle performance and vastus medialis volume was found only with the eccentric rehabilitation. This study confirms the importance of any type of rehabilitation in knee osteoarthritis and raises the question of the relation between muscle gain/performance and function or painAcknowledgements:We would like to thank all the patients who took part in the study as well as all the members of the Fragile Platform of the Nice University Hospital.Disclosure of Interests:None declared
Collapse
|
22
|
Bottois C, López-Medina C, Dumas S, Julien H, Sephora B, Roux C, Moltó A, Conort O, Dougados M. POS0273-HPR PHARMACIST’S IMPACT ON SELF-MANAGEMENT FOR PATIENTS WITH CHRONIC INFLAMMATORY ARTHRITIS TREATED WITH BIOLOGICAL DMARDS. Ann Rheum Dis 2021. [DOI: 10.1136/annrheumdis-2021-eular.2135] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
Background:Knowledge about chronic inflammatory rheumatisc diseases and skills to administer and manage subcutaneous (subcut) biological DMARDs (bDMARDs) are key aspects to optimize patient’s self-management. Intervention of several successive health professionals (e.g comprehensive multidisciplinary team) has proven to be an effective method to improve patient’s self-management of their disease and treatment.Objectives:To assess the pharmacist’s impact on patient’s knowledge and skills during a multidisciplinary annual review. The secondary objectives were to assess this impact on therapeutic adherence and patient’s satisfaction as well as to determine the factors associated with the level of knowledge at baseline.Methods:Study type: prospective, monocentric, 6 months-follow-up, non-controlled study approved by Local Ethical Committee. Inclusion criteria: patient with either rheumatoid arthritis (RA) or spondyloarthritis (SpA), and treated with subcut bDMARDs. Intervention: The visit with a pharmacist evaluating and discussing patient’s knowledge and treatment adherence. At baseline (M0): date of the visit and, 3 (M3) and 6 months (M6) later, knowledge and adherence were assessed using self-administered questionnaires: Biosecure and CQR-5 respectively. A questionnaire was sent at M3 in order to evaluate the patient satisfaction. Endpoints: Primary: Changes in Biosecure score Secondary: Percentage of patients with high level of knowledge (score > 84) and percentage of patients with high adherence at M3 and M6; patient’s satisfaction; identification of patient’s factors (socio-demographics, rheumatisc disease treatments) associated with different levels of knowledge at baseline.Statistical analysis: repeated measures ANOVA, Bonferroni and Generalized Estimating Equation, univariate and multivariate linear regression.Results:The study was conducted from October 2019 to July 2020; 79 patients were included (age (years) = 50±15; sex ratio = 1.1; RA=25, SpA=54). The Biosecure scores changed from 71±18 to 82±15 (M3) and to 84±14 (M6) (p<0.001). At M0, M3 and M6, the rate of patients with a high level of knowledge was 24.1%, 59.5% and 63.3% respectively (p<0.001). No difference was observed for the change in the 92% of patients considered as high adherent (92% versus 95% at M0 and M6 respectively; p=0.077). Patient’s satisfaction regarding the pharmaceutical intervention was 25±3 (max = 28).Factors associated with a better Biosecure score in the multivariate analysis were the following, lifestyle as a couple (p<0.001), information given by a nurse (p=0.033), information searched for on patient associations (p=0.013) and a low Charlson score (p=0.001)Conclusion:Pharmacist’s intervention in the comprehensive multidisciplinary annual review resulted in a beneficial impact on patients’ knowledge and skills to manage their bDMARDs with a high level of satisfaction from a patient perspective.Disclosure of Interests:None declared
Collapse
|
23
|
Portier E, Dougados M, Roux C, Moltó A. POS0188 DISEASE ACTIVITY OUTCOME MEASURES ARE ONLY AVAILABLE IN HALF OF THE ELECTRONIC MEDICAL FILES OF PATIENTS WITH AXIAL SPONDYLOARTHRITIS FOLLOWED IN AN OUTPATIENT CLINIC: THE RESULTS OF AN AUDIT OF A TERTIARY-CARE RHEUMATOLOGY DEPARTMENT. Ann Rheum Dis 2021. [DOI: 10.1136/annrheumdis-2021-eular.2120] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
Background:Current recommendations for management of patients with axial Spondylarthritis (axSpA) include regular collection of validated disease activity outcomes.Objectives:This study aimed at evaluating the proportion of patients for whom the elements allowing the calculation of the validated outcome measures were available on the visits reported on the electronic medical records (EMR) and the factors associated with the presence of such information on the EMR.Methods:This was a cross-sectional and monocentric observational study conducted in a tertiary-care rheumatology department, EULAR center of excellence and ASAS center. We performed a systematic electronic search among all patients with a SpA diagnosis code who attended an outpatient visit between February 1st, 2018 and February 28th, 2019. Thereafter, a manual search was performed in order to check whether disease activity outcome measures (or the elements allowing its calculation): BASDAI individual questions, Disease activity Global, CRP, BASDAI and ASDAS) were reported on EMR. Patient’s and physician’s demographics disease characteristics (including treatment) and whether the patient had participated in a systematic review were also collected. A descriptive analysis of the percentage of EMR with available outcomes was performed, and the characteristics of patients in whom these measures were available/were not available evaluated by univariable and multivariable analysis (including only variables with p < 0,10 on the univariate)Results:320 EMR of axSpA patients seen in the outpatient clinic were screened and selected. Among them, 178 (55.6%) had at least one disease activity outcome measure reported, while 144(45%) and 123 (38.4%) had a BASDAI and an ASDAS reported, respectively. The most frequently reported disease activity items were duration of morning stiffness (n=230, 72%) and CRP (n=224, 70%).Only previous participation on an educational program for self-assessment was found to be independently associated with a reported disease activity outcome: among the patients participating in such program, 93.1% (n=27/29) had a disease activity measure available, compared to 51.9% (n=151/291) in those who did not participate in such program (p<0.001) (Table 1)Conclusion:Implementation of recommendations with regard to regularly collecting disease activity outcome measures is not optimal. The participation in educational programs including self-assessment educational programs might be one of the keys to improve such implementation.References:[1]Smolen JS, Braun J, Dougados M, Emery P, Fitzgerald O, Helliwell P, et al. Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force. Ann Rheum Dis 2014;73:6–16. https://doi.org/10.1136/annrheumdis-2013-203419.[2]van der Heijde D, Ramiro S, Landewé R, Baraliakos X, Van den Bosch F, Sepriano A, et al. 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. Ann Rheum Dis 2017;76:978–91. https://doi.org/10.1136/annrheumdis-2016-210770.Figure 1.Frequency of disease activity measures reporting in the Electronic Medical Record of patients with axial Spondyloarthritis, followed in a tertiary care rheumatology department outpatient clinicTable 1.Factors associated with the presence of a reported disease activity measures on the electronic medical file of patients with axial SpADisclosure of Interests:Elodie Portier: None declared, Maxime Dougados: None declared, Christian Roux: None declared, Anna Moltó Consultant of: Abbvie, BMS, MSD, Pfizer, Lilly, UCB Novartis, Grant/research support from: Pfizer
Collapse
|
24
|
Roux C, Sbidian E, Bouaziz JD, Kottler D, Joly P, Prost C, Samimi M, Seneschal J, Dupin N, Girard C, Le Cléach L, Oro S. Intérêt du thalidomide en traitement continu des érythèmes polymorphes chroniques. Ann Dermatol Venereol 2020. [DOI: 10.1016/j.annder.2020.09.131] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
25
|
Mahé E, Avenel-Audran M, Schmutz JL, Jeanmougin M, Aubin F, Thomas P, De Paula Corrêa M, Godin-Beekmann S, Ionescu MA, Roux C, Beauchet A, Bellil V. Sportifs en plein air, comparaison multisports des connaissances et comportements sur la protection solaire. Ann Dermatol Venereol 2020. [DOI: 10.1016/j.annder.2020.09.352] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
26
|
Tselikas L, Garzelli L, Mercier O, Auperin A, Lamrani L, Deschamps F, Yevich S, Roux C, Mussot S, Delpla A, Varin F, Hakime A, Teriitehau C, Le Péchoux C, Pradère P, Caramella C, Besse B, Fadel E, de Baere T. Radiofrequency ablation versus surgical resection for the treatment of oligometastatic lung disease. Diagn Interv Imaging 2020; 102:19-26. [PMID: 33020025 DOI: 10.1016/j.diii.2020.09.006] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/05/2020] [Revised: 08/13/2020] [Accepted: 09/01/2020] [Indexed: 12/14/2022]
Abstract
PURPOSE The purpose of this study was to compare efficacy and tolerance between radiofrequency ablation (RFA) and surgery for the treatment of oligometastatic lung disease. MATERIALS AND METHODS This retrospective study reviewed patients treated in two institutions for up to 5 pulmonary metastases with a maximal diameter of 4cm and without associated pleural involvement or thoracic lymphadenopathy. Patient demographics, tumor characteristics, treatment outcome, and length of hospital stay were compared between the two groups. Efficacy endpoints were overall survival (OS), progression-free survival (PFS) and pulmonary or local tumor progression rates. RESULTS Among 204 patients identified, 78 patients (42 men, 36 women; mean age, 53.3±14.9 [SD]; age range: 15-81 years) were treated surgically, while 126 patients (59 men, 67 women; mean age, 62.2±10.8 [SD]; age range: 33-80 years) were treated by RFA. In the RFA cohort, patients were significantly older (P<0.0001), with more extra-thoracic localisation (P=0.015) and bilateral tumour burden (P=0.0014). In comparison between surgery and RFA cohorts, respectively, the 1- and 3-year OS were 94.8 and 67.2% vs. 94 and 72.1% (P=0.46), the 1- and 3-year PFS were 49.4% and 26.1% vs. 38.9% and 14.8% (P=0.12), the pulmonary progression rates were 39.1% and 56% vs. 41.2% and 65.3% (P>0.99), and the local tumour progression rates were 5.4% and 10.6% vs. 4.8% and 18.6% (P=0.07). Tumour size>2cm was associated with a significantly higher local tumor progression in the RFA group (P=0.010). Hospitalisation stay was significantly shorter in the RFA group (median of 3 days; IQR=2 days; range: 2-12 days) than in the surgery group (median of 9 days; IQR=2 days; range: 6-21 days) (P<0.01). CONCLUSION RFA should be considered a minimally-invasive alternative with similar OS and PFS to surgery in the treatment of solitary or multiple lung metastases measuring less than 4cm in diameter without associated pleural involvement or thoracic lymphadenopathy.
Collapse
Affiliation(s)
- L Tselikas
- Interventional Radiology, Gustave-Roussy Cancer Campus, 94805 Villejuif, France; University of Paris-Saclay, 91190 Saint-Aubin, France; Institut d'Oncologie thoracique, 94805 Villejuif, France.
| | - L Garzelli
- Interventional Radiology, Gustave-Roussy Cancer Campus, 94805 Villejuif, France
| | - O Mercier
- University of Paris-Saclay, 91190 Saint-Aubin, France; Institut d'Oncologie thoracique, 94805 Villejuif, France; Department of Thoracic and Vascular Surgery, Marie-Lannelongue Hospital, 92350 Le Plessis-Robinson, France; Research and Innovation Unit, INSERM U999, DHU Torino, Marie-Lannelongue Hospital, 92350 Le Plessis-Robinson, France
| | - A Auperin
- Biostatistics and Epidemiology Unit, Gustave-Roussy INSERM 1018, 94805 Villejuif, France
| | - L Lamrani
- Research and Innovation Unit, INSERM U999, DHU Torino, Marie-Lannelongue Hospital, 92350 Le Plessis-Robinson, France
| | - F Deschamps
- Interventional Radiology, Gustave-Roussy Cancer Campus, 94805 Villejuif, France
| | - S Yevich
- Interventional Radiology, Gustave-Roussy Cancer Campus, 94805 Villejuif, France; Interventional Radiology, MD-Anderson, 77030 Houston, TX, USA
| | - C Roux
- Interventional Radiology, Gustave-Roussy Cancer Campus, 94805 Villejuif, France
| | - S Mussot
- Institut d'Oncologie thoracique, 94805 Villejuif, France; Department of Thoracic and Vascular Surgery, Marie-Lannelongue Hospital, 92350 Le Plessis-Robinson, France; Research and Innovation Unit, INSERM U999, DHU Torino, Marie-Lannelongue Hospital, 92350 Le Plessis-Robinson, France
| | - A Delpla
- Interventional Radiology, Gustave-Roussy Cancer Campus, 94805 Villejuif, France
| | - F Varin
- Department of Anesthesiology, Gustave-Roussy Cancer Campus, 94805 Villejuif, France
| | - A Hakime
- Interventional Radiology, Gustave-Roussy Cancer Campus, 94805 Villejuif, France
| | - C Teriitehau
- Interventional Radiology, Gustave-Roussy Cancer Campus, 94805 Villejuif, France
| | - C Le Péchoux
- Institut d'Oncologie thoracique, 94805 Villejuif, France; Department of Radiation Therapy, Gustave-Roussy Cancer Campus, 94805 Villejuif, France
| | - P Pradère
- Institut d'Oncologie thoracique, 94805 Villejuif, France; Department of Thoracic and Vascular Surgery, Marie-Lannelongue Hospital, 92350 Le Plessis-Robinson, France
| | - C Caramella
- Institut d'Oncologie thoracique, 94805 Villejuif, France; Radiology Department, Marie-Lannelongue Hospital, 92350 Le Plessis-Robinson, France
| | - B Besse
- University of Paris-Saclay, 91190 Saint-Aubin, France; Institut d'Oncologie thoracique, 94805 Villejuif, France; Department of Cancer Medicine, Gustave-Roussy Cancer Campus, 94805 Villejuif, France
| | - E Fadel
- University of Paris-Saclay, 91190 Saint-Aubin, France; Institut d'Oncologie thoracique, 94805 Villejuif, France; Department of Thoracic and Vascular Surgery, Marie-Lannelongue Hospital, 92350 Le Plessis-Robinson, France; Research and Innovation Unit, INSERM U999, DHU Torino, Marie-Lannelongue Hospital, 92350 Le Plessis-Robinson, France
| | - T de Baere
- Interventional Radiology, Gustave-Roussy Cancer Campus, 94805 Villejuif, France; University of Paris-Saclay, 91190 Saint-Aubin, France; Institut d'Oncologie thoracique, 94805 Villejuif, France
| |
Collapse
|
27
|
Bianchi ML, Bishop NJ, Guañabens N, Hofmann C, Jakob F, Roux C, Zillikens MC. Hypophosphatasia in adolescents and adults: overview of diagnosis and treatment. Osteoporos Int 2020; 31:1445-1460. [PMID: 32162014 DOI: 10.1007/s00198-020-05345-9] [Citation(s) in RCA: 20] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/22/2019] [Accepted: 02/11/2020] [Indexed: 12/11/2022]
Abstract
This article provides an overview of the current knowledge on hypophosphatasia-a rare genetic disease of very variable presentation and severity-with a special focus on adolescents and adults. It summarizes the available information on the many known mutations of tissue-nonspecific alkaline phosphatase (TNSALP), the epidemiology and clinical presentation of the disease in adolescents and adults, and the essential diagnostic clues. The last section reviews the therapeutic approaches, including recent reports on enzyme replacement therapy (EnzRT).
Collapse
Affiliation(s)
- M L Bianchi
- Laboratorio sperimentale di ricerche sul metabolismo osseo infantile, Centro Malattie Metaboliche Ossee, Istituto Auxologico Italiano IRCCS, Milan, Italy.
| | - N J Bishop
- Department of Oncology and Metabolism, University of Sheffield, Sheffield Children's NHS Foundation Trust, Sheffield, UK
| | - N Guañabens
- Servicio de Reumatología, Hospital Clínic, Universidad de Barcelona, IDIBAPS CIBERehd, Barcelona, Spain
| | - C Hofmann
- Children's Hospital, University of Würzburg, Würzburg, Germany
| | - F Jakob
- Orthopedic Centre for Musculoskeletal Research, University of Würzburg, Würzburg, Germany
| | - C Roux
- INSERM U1153 APHP Centre, Université de Paris, Department of Rheumatology, Paris, France
| | - M C Zillikens
- Department of Internal Medicine, Endocrinology Section, Erasmus Medical Centre, Rotterdam, The Netherlands
| | | |
Collapse
|
28
|
Peran M, Allado E, Albuisson E, Couderc M, Ornetti P, Roux C, Grosse J, Chary Valckenaere I, Loeuille D. AB1125 PERFORMANCE OF ULTRASOUNDS TO ASSESS EROSION PROGRESSION IN RHEUMATOID ARTHRITIS. Ann Rheum Dis 2020. [DOI: 10.1136/annrheumdis-2020-eular.2444] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
Background:Ultrasonography (US) can detect more erosions than radiography (RX) at the joint level in rheumatoid arthritis (RA), especially at an early stage of the disease.Objectives:The aim of the study is to determine the ability of ultrasonography to detect erosion progression by the US Score for erosions (USSe), in early (less than 2 years disease duration (DD)) and late stage (more than 2 years DD) RA over two years of follow-up.Methods:Patients fulfilling ACR 1987 and/or ACR/EULAR 2010 criteria for RA were prospectively included. Clinical and demographic informations were recorded at baseline and hands and feet RX were scored according to the Sharp erosion score (SHSe). Erosive RA on RX was defined by the presence of at least three eroded joints (1). US examinations were performed at baseline and during the two years of follow-up. Erosions were scored by US on six bilateral joints (MCP 2, 3, 5 and MTP 2, 3, 5) with a four grade-scale to calculate total USSe. Erosive RA on US was defined by presence of one erosion ≥ 2mm (2). Inter-examiner reproducibility was performed on 14 patients in order to calculate the smallest detectable change (SDC), which was 2.3. Ultrasonographic progression was defined as a change in USSe > 2 (erosion change > SDC).Results:A total of 71 patients were included, 22 patients (31.0%) had early RA and 49 (69.0%) patients had late RA diseases. On RX, 30 (42.3%) patients were erosive at baseline with a mean SHSe at 29.4 (SD at 24.7). On US, 63 patients (88.7%) were classified as eroded. On US, erosions prevailed at baseline in MTP5 joints, then MCP2 and MCP5 joints on their lateral facets. During follow-up, 28 patients (39.4%) were classified as US progressors, 30 (42.3%) were stable and 13 (18.3%) considered as regressors (figure 1). In early RA disease, three of the four non eroded patients became eroded. USSe progressed in 11 patients (50%) while regression was observed in only one patient. In late RA disease, 17 patients (34.7%) progressed and 12 patients (24.5%) decreased significantly their USSe. Erosion progression prevailed on MTP 5 joints followed by MCP2 and finally MCP5 joints (figure 2).Figure 1.USSe progression plots (n=71)Figure 2.Differences of USSe by joints during follow-up in early and late RAConclusion:US structural examination is a highly reproducible method to assess erosion in RA disease. The USSe is able to detect structural changes (progression, stabilization and regression) in RA patients during a follow-up of two years especially in RA patients with short disease duration.References:[1]Van der Heijde D, van der Helm-van Mil AHM, Aletaha D, Bingham CO, Burmester GR, Dougados M, et al. EULAR definition of erosive disease in light of the 2010 ACR/EULAR rheumatoid arthritis classification criteria. Ann Rheum Dis. avr 2013;72(4):479‑81.[2]Roux C, Gandjbakhch F, Pierreisnard A, Couderc M, Lukas C, Masri R, et al. Optimization of ultrasonographic examination for the diagnosis of erosive Rheumatoid Arthritis in comparison to erosive hand Osteoarthritis. Eur J Radiol. sept 2019;118:10‑8.Disclosure of Interests:None declared
Collapse
|
29
|
Richebé P, Godot S, Coiffier G, Guggenbuhl P, Mulleman D, Couderc M, Dernis E, Deprez V, Salliot C, Urien S, Brault R, Ruyssen-Witrand A, Hoppe E, Gottenberg JE, Roux C, Ottaviani S, Breban M, Beaufrere M, Michaut A, Pauvele L, Darrieutort C, Wendling D, Coquerelle P, Bart G, Gervais E, Goeb V, Ardizzone M, Pertuiset E, Derolez S, Ziza JM, Flipo RM, Seror R. FRI0449 MANAGEMENT AND OUTCOME OF SEPTIC ARTHRITIS OF NATIVE JOINT: A NATIONWIDE SURVEY. Ann Rheum Dis 2020. [DOI: 10.1136/annrheumdis-2020-eular.5817] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
Background:Objectives:To describe current management and outcome of septic arthritis on native joint in French rheumatology departments.Methods:Retrospective, nation-wide multicentric study. 127 French rheumatology departments were contacted to report 10 successive cases of septic arthritis on native joint that occurred between the 01/01/16 to 31/12/17 (excluding mycobacteria). Characteristics, diagnosis procedure, therapeutic management and outcome were recorded.Results:52 centers included 363 patients (mean age 64± 18.7 years, mean Charlson comorbidity index 4±3). 28.3% patients had a preexisting arthropathy on affected joint. Monoarthritis was observed in 89.6% patients, knee was the most frequent site (38.9%). The most frequent pathogens wereStaphylococcus sp(50.7%) andStreptococcus sp.(23.3%). Bacteremia was found in 156 (45.1%) patients and endocarditis in only 12 (3.0%). Management was heterogeneous. All patients received antibiotics for a mean duration of 46.7±22 days (including intravenous route: 17.3±15.4 d). An initial monotherapy was administered in 42.3% of patients. Surgical procedure (mostly lavage 70.6%) was performed in 171 (48.3%), joint immobilization in 128 (35.3%) (median duration of 21.7±14.1 days). 94 (29.2%) patients have had serious complications including 29 (9.5%) death. Factors associated with death are reported in the table.Conclusion:This study shows that management of septic arthritis is very heterogenous with a still high rate of morbidity and mortality. We identified age, comorbidities, bacteremia and recent antibiotherapy were associated with mortality. Of note, duration of antibiotics was not. Thus, new guidelines are needed in order to facilitate septic arthritis management.Table:FactorsSurvivor(N=276)Dead(N=29)Univariate analysispAdjusted Odds ratio (95%IC)Multivariate analysispAge65 (16-97)82 (32-98)<0,0011,07 (1,03-1,12)< 0.001Charlson’s index1 (0-12)2 (0-9)0,00011,3 (1,05-1,63)0,018Delay before antibiotic initiation8,5 (0-310)5 (0-75)0,04840,99 (0,96-1,02)0,562Corticosteroid in the previous 3 months13,9%33,3%0,01842,56 (0,75-8,74)0,133Bacteriemia42,4%71,4%0,00615,07 (1,4-18,370,013Antibiotics in the previous 3 months26,6%56,6%0,00566,7 (2,04-22,01)0,002Disclosure of Interests:Pauline Richebé: None declared, Sophie Godot: None declared, Guillaume Coiffier: None declared, Pascal GUGGENBUHL: None declared, Denis Mulleman: None declared, Marion Couderc: None declared, Emmanuelle Dernis Speakers bureau: Lilly, Novartis, Valentine Deprez: None declared, Carine Salliot: None declared, Saik Urien: None declared, Rachel Brault: None declared, Adeline Ruyssen-Witrand Grant/research support from: Abbvie, Pfizer, Consultant of: Abbvie, BMS, Lilly, Mylan, Novartis, Pfizer, Sandoz, Sanofi-Genzyme, Emmanuel Hoppe: None declared, Jacques-Eric Gottenberg Grant/research support from: BMS, Pfizer, Consultant of: BMS, Sanofi-Genzyme, UCB, Speakers bureau: Abbvie, Eli Lilly and Co., Roche, Sanofi-Genzyme, UCB, Christian Roux: None declared, Sebastien Ottaviani: None declared, Maxime Breban: None declared, Marie Beaufrere: None declared, Alexia Michaut: None declared, Loic Pauvele: None declared, Christelle Darrieutort: None declared, Daniel Wendling: None declared, Pascal COQUERELLE: None declared, Géraldine Bart: None declared, Elisabeth Gervais: None declared, Vincent Goeb: None declared, Marc Ardizzone: None declared, Edouard Pertuiset: None declared, Sophie Derolez: None declared, Jean Marc Ziza: None declared, René-Marc Flipo Consultant of: Johnson and Johnson, MSD France, Novartis, Sanofi, Speakers bureau: Johnson and Johnson, MSD France, Novartis, Sanofi, Raphaèle Seror Consultant of: BMS UCB Pfizer Roche
Collapse
|
30
|
Garofoli R, Resche-Rigon M, Dougados M, Van der Heijde D, Roux C, Moltó A. SAT0587 MACHINE-LEARNING DERIVED ALGORITHMS FOR OUTCOMES PREDICTION IN RHEUMATIC DISEASES: APPLICATION TO RADIOGRAPHIC PROGRESSION IN EARLY AXIAL SPONDYLOARTHRITIS. Ann Rheum Dis 2020. [DOI: 10.1136/annrheumdis-2020-eular.431] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
Background:Axial spondyloarthritis (axSpA) is a chronic rheumatic disease that encompasses various clinical presentations: inflammatory chronic back pain, peripheral manifestations and extra-articular manifestations. The current nomenclature divides axSpA in radiographic (in the presence of radiographic sacroiliitis) and non-radiographic (in the absence of radiographic sacroiliitis, with or without MRI sacroiliitis. Given that the functional burden of the disease appears to be greater in patients with radiographic forms, it seems crucial to be able to predict which patients will be more likely to develop structural damage over time. Predictive factors for radiographic progression in axSpA have been identified through use of traditional statistical models like logistic regression. However, these models present some limitations. In order to overcome these limitations and to improve the predictive performance, machine learning (ML) methods have been developed.Objectives:To compare ML models to traditional models to predict radiographic progression in patients with early axSpA.Methods:Study design: prospective French multicentric cohort study (DESIR cohort) with 5years of follow-up. Patients: all patients included in the cohort, i.e. 708 patients with inflammatory back pain for >3 months but <3 years, highly suggestive of axSpA. Data on the first 5 years of follow-up was used. Statistical analyses: radiographic progression was defined as progression either at the spine (increase of at least 1 point per 2 years of mSASSS scores) or at the sacroiliac joint (worsening of at least one grade of the mNY score between 2 visits). Traditional modelling: we first performed a bivariate analysis between our outcome (radiographic progression) and explanatory variables at baseline to select the variables to be included in our models and then built a logistic regression model (M1). Variable selection for traditional models was performed with 2 different methods: stepwise selection based on Akaike Information Criterion (stepAIC) method (M2), and the Least Absolute Shrinkage and Selection Operator (LASSO) method (M3). We also performed sensitivity analysis on all patients with manual backward method (M4) after multiple imputation of missing data. Machine learning modelling: using the “SuperLearner” package on R, we modelled radiographic progression with stepAIC, LASSO, random forest, Discrete Bayesian Additive Regression Trees Samplers (DBARTS), Generalized Additive Models (GAM), multivariate adaptive polynomial spline regression (polymars), Recursive Partitioning And Regression Trees (RPART) and Super Learner. Finally, the accuracy of traditional and ML models was compared based on their 10-foldcross-validated AUC (cv-AUC).Results:10-fold cv-AUC for traditional models were 0.79 and 0.78 for M2 and M3, respectively. The 3 best models in the ML algorithm were the GAM, the DBARTS and the Super Learner models, with 10-fold cv-AUC of: 0.77, 0.76 and 0.74, respectively (Table 1).Table 1.Comparison of 10-fold cross-validated AUC between best traditional and machine learning models.Best modelsCross-validated AUCTraditional models M2 (step AIC method)0.79 M3 (LASSO method)0.78Machine learning approach SL Discrete Bayesian Additive Regression Trees Samplers (DBARTS)0.76 SL Generalized Additive Models (GAM)0.77 Super Learner0.74AUC: Area Under the Curve; AIC: Akaike Information Criterion; LASSO: Least Absolute Shrinkage and Selection Operator; SL: SuperLearner. N = 295.Conclusion:Traditional models predicted better radiographic progression than ML models in this early axSpA population. Further ML algorithms image-based or with other artificial intelligence methods (e.g. deep learning) might perform better than traditional models in this setting.Acknowledgments:Thanks to the French National Society of Rheumatology and the DESIR cohort.Disclosure of Interests:Romain Garofoli: None declared, Matthieu resche-rigon: None declared, Maxime Dougados Grant/research support from: AbbVie, Eli Lilly, Merck, Novartis, Pfizer and UCB Pharma, Consultant of: AbbVie, Eli Lilly, Merck, Novartis, Pfizer and UCB Pharma, Speakers bureau: AbbVie, Eli Lilly, Merck, Novartis, Pfizer and UCB Pharma, Désirée van der Heijde Consultant of: AbbVie, Amgen, Astellas, AstraZeneca, BMS, Boehringer Ingelheim, Celgene, Cyxone, Daiichi, Eisai, Eli-Lilly, Galapagos, Gilead Sciences, Inc., Glaxo-Smith-Kline, Janssen, Merck, Novartis, Pfizer, Regeneron, Roche, Sanofi, Takeda, UCB Pharma; Director of Imaging Rheumatology BV, Christian Roux: None declared, Anna Moltó Grant/research support from: Pfizer, UCB, Consultant of: Abbvie, BMS, MSD, Novartis, Pfizer, UCB
Collapse
|
31
|
Gossec L, Flipo RM, Schaeverbeke T, Albert C, Baillet A, Boissier MC, Confavreux C, Cormier G, Dernis E, Gervais Solau E, Godot S, Gottenberg JE, Goupille P, Lassoued S, Lequerre T, Lioté F, Marcelli C, Maugars Y, Nguyen M, Perdriger A, Pers YM, Pertuiset E, Poiroux L, Rosenberg C, Roux C, Ruyssen-Witrand A, Soubrier M, Vergne-Salle P, Zarnitsky C, Fakra E, Marotte H, Lévy-Weil FE. FRI0095 SARILUMAB IMPROVED PATIENT-PERCEIVED IMPACT OF RHEUMATOID ARTHRITIS WHATEVER THE BASELINE DISEASE ACTIVITY: FIRST RESULTS FROM AN INTERVENTIONAL NON CONTROLLED STUDY: SARIPRO, IN MODERATE AND SEVERE RHEUMATOID ARTHRITIS PATIENTS. Ann Rheum Dis 2020. [DOI: 10.1136/annrheumdis-2020-eular.5518] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
Background:Sarilumab, an anti-IL-6R antibody, is approved for the treatment of moderate to severe RA and shown efficacy on disease activity and patient-reported outcomes (PROs). Detailed analyses of drug efficacy from the patient point of view is important. SariPRO is a pragmatic interventional study close to the daily practice.Objectives:To assess the effectiveness of sarilumab on several PROs using the RAID (Rheumatoid Arthritis Impact of Disease) score.Methods:The SariPRO study (NCT 03449758) was a French multicenter interventional study assessing the effects of sarilumab 200 mg on PROs in patients with moderately to severely active RA with an inadequate response or intolerance to conventional synthetic or biologic DMARDs. The primary endpoint was change in total RAID score from baseline to week 24 (RAID ranges 0-10 where 10 is maximal impact). Changes from baseline for RAID, DAS28-ESR and CDAI according to baseline disease activity were analyzed as secondary outcomes. Safety was assessed by monitoring adverse events (AE). All statistical analyses were descriptive, 95% CI was given when appropriate.Results:84 patients were included in 31 centers and 62 were evaluable and analyzed for effectiveness. They had similar characteristics to the 84 patients at baseline and were as expected for an RA population initiating a biologic: mean (SD) age: 59.9 (12.4) years, 71.0% female, disease duration 9.7 (10.3) years, rheumatoid factor positivity 82.5%, ACPA positivity 86.4%, and DAS28=4.9 (11). Total RAID score decreased significantly from 5.7 (2.0) at baseline to 3.3 (2.5) at W24; mean change was -2.4 [95% CI: -3.0; -1.8]. Furthermore, this improvement was noted both for highly and less active patients at baseline: for patients with DAS28-ESR < 5.1 (n=31), mean change was -1.56 [-2.28; -0.83] and for patients with DAS28-ESR≥5.1 (n=27), mean change was -1.98 [-2.91; -1.05]. Changes in DAS28-ESR and CDAI were significant (-2.8 [-3.2; -2.4] and -15.2 [-18.5; -11.8], respectively). AEs were consistent with the safety profile of anti-IL-6R antibodies and with results from RCTs (data not shown).Conclusion:In this real world study, treatment with sarilumab during 24 weeks in RA patients led to an improvement in the total RAID score irrespective of baseline levels of disease activity. This is the first time RAID score is used as the primary endpoint in a study.References:[1]Study was sponsored by Sanofi GenzymeDisclosure of Interests:Laure Gossec Grant/research support from: Lilly, Mylan, Pfizer, Sandoz, Consultant of: AbbVie, Amgen, Biogen, Celgene, Janssen, Lilly, Novartis, Pfizer, Sandoz, Sanofi-Aventis, UCB, René-Marc Flipo Consultant of: Johnson and Johnson, MSD France, Novartis, Sanofi, Speakers bureau: Johnson and Johnson, MSD France, Novartis, Sanofi, Thierry Schaeverbeke: None declared, Christine Albert: None declared, Athan Baillet Consultant of: Athan BAILLET has received honorarium fees from Abbvie for his participation as the coordinator of the systematic literature review, marie-Christophe Boissier: None declared, Cyrille Confavreux: None declared, Gregoire CORMIER: None declared, Emmanuelle Dernis Speakers bureau: Lilly, Novartis, Elisabeth Gervais Solau: None declared, Sophie Godot: None declared, Jacques-Eric Gottenberg Grant/research support from: BMS, Pfizer, Consultant of: BMS, Sanofi-Genzyme, UCB, Speakers bureau: Abbvie, Eli Lilly and Co., Roche, Sanofi-Genzyme, UCB, Philippe Goupille Grant/research support from: AbbVie, Amgen, Biogen, BMS, Celgene, Chugai, Lilly, Janssen, Medac, MSD France, Nordic Pharma, Novartis, Pfizer, Sanofi and UCB, Consultant of: AbbVie, Amgen, Biogen, BMS, Celgene, Chugai, Lilly, Janssen, Medac, MSD France, Nordic Pharma, Novartis, Pfizer, Sanofi and UCB, Speakers bureau: AbbVie, Amgen, Biogen, BMS, Celgene, Chugai, Lilly, Janssen, Medac, MSD France, Nordic Pharma, Novartis, Pfizer, Sanofi and UCB, Slim Lassoued: None declared, Thierry Lequerre: None declared, Frederic Lioté Consultant of: CME: Nordic Pharma, Christian Marcelli: None declared, Yves Maugars: None declared, Minh Nguyen: None declared, Aleth Perdriger: None declared, Yves-Marie Pers: None declared, Edouard Pertuiset: None declared, Lucile Poiroux: None declared, Carole Rosenberg: None declared, Christian Roux: None declared, Adeline Ruyssen-Witrand Grant/research support from: Abbvie, Pfizer, Consultant of: Abbvie, BMS, Lilly, Mylan, Novartis, Pfizer, Sandoz, Sanofi-Genzyme, Martin SOUBRIER: None declared, Pascale Vergne-Salle: None declared, Charles Zarnitsky: None declared, Eric Fakra Consultant of: Janssen, Lundbeck, Otsuka, Sanofi, Hubert MAROTTE Grant/research support from: Bristol Myers Sqibb, Lilly France, MSD, Novartis, Nordic Pharma, Pfizer, SanofiAventis, Consultant of: AbbVie, Amgen, Bristol Myers Sqibb, Lilly France, MSD, Novartis, Nordic Pharma, Pfizer, SanofiAventis, Paid instructor for: Sanofi-Aventis, Speakers bureau: Sanofi-Aventis, Florence E Lévy-Weil Employee of: Sanofi Genzyme employee
Collapse
|
32
|
Martin A, Landesman C, Lépinay A, Roux C, Champion J, Chardon P, Montavon G. Flow period influence on uranium and trace elements release in water from the waste rock pile of the former La Commanderie uranium mine (France). J Environ Radioact 2019; 208-209:106010. [PMID: 31302578 DOI: 10.1016/j.jenvrad.2019.106010] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/20/2019] [Revised: 06/25/2019] [Accepted: 06/30/2019] [Indexed: 06/10/2023]
Abstract
Uranium mining activities expose uranium ore and mine tailings to the surface environment, where the release of radionuclides is facilitated by weathering at rates exceeding those typically found in nature. Therefore, close to former uranium mining sites, radionuclides and especially uranium concentrations in water may surpass local background levels. The methodology proposed herein, entails coupling, gamma-ray mapping, water sampling and chemical analyses including DGT (Diffusive Gradient in Thin Film) measurements, provides new insights into describing the environment of the La Commanderie site (France). Gamma-ray mapping allows identifying water seepage, output from a waste rock pile, as a potential pathway for radionuclides into the environment. Water seepage monitoring has shown: a low pH value (4.2), high sulfate content (179 mg.L-1) and high uranium concentrations of up to 436 μg.L-1. These recordings indicate that an acid mining drainage (AMD) process is occurring inside or under the oxidized parts of the waste rock pile. Monitoring data over three flow periods revealed the release of the highest uranium concentrations during a high-flow period downstream of the site, which is compliant with local regulations. The AMD process is also responsible for the release of significant amounts of Fe, Mn and As within the immediate environment in both dissolved and particulate forms. Changes in dissolved oxygen concentration and redox potential during low flow periods, modify the speciation of Fe (in AMD waters) which acts as a scavenger for other elements such as As, Mn and U. The use of DGT under environmental conditions, and specifically AMD waters, seems to be relevant in comparison to filtered spot water sampling strategies. Moreover, based on DGT measurements, the dissolved part of the released uranium is considered as labile with concentrations above the environmental standards for freshwater organisms.
Collapse
Affiliation(s)
- A Martin
- SUBATECH, UMR 6457 (IMT-Atlantique, Université de Nantes, CNRS-IN2P3), 4 rue Alfred Kastler, 44307, Nantes, France
| | - C Landesman
- SUBATECH, UMR 6457 (IMT-Atlantique, Université de Nantes, CNRS-IN2P3), 4 rue Alfred Kastler, 44307, Nantes, France.
| | - A Lépinay
- Université de Nantes/OSUNA, UMR 3281, 2 rue de la Houssinière, 44322, Nantes Cedex, France
| | - C Roux
- SUBATECH, UMR 6457 (IMT-Atlantique, Université de Nantes, CNRS-IN2P3), 4 rue Alfred Kastler, 44307, Nantes, France
| | - J Champion
- SUBATECH, UMR 6457 (IMT-Atlantique, Université de Nantes, CNRS-IN2P3), 4 rue Alfred Kastler, 44307, Nantes, France
| | - P Chardon
- LPC, UMR 6533 (IN2P3/CNRS/Université Clermont Auvergne), 4 Avenue Blaise Pascal TSA60026, CS60026, 63178, Aubière Cedex, France
| | - G Montavon
- SUBATECH, UMR 6457 (IMT-Atlantique, Université de Nantes, CNRS-IN2P3), 4 rue Alfred Kastler, 44307, Nantes, France
| |
Collapse
|
33
|
Minonzio JG, Bochud N, Vallet Q, Ramiandrisoa D, Etcheto A, Briot K, Kolta S, Roux C, Laugier P. Ultrasound-Based Estimates of Cortical Bone Thickness and Porosity Are Associated With Nontraumatic Fractures in Postmenopausal Women: A Pilot Study. J Bone Miner Res 2019; 34:1585-1596. [PMID: 30913320 DOI: 10.1002/jbmr.3733] [Citation(s) in RCA: 32] [Impact Index Per Article: 6.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/18/2018] [Revised: 02/21/2019] [Accepted: 03/10/2019] [Indexed: 01/02/2023]
Abstract
Recent ultrasound (US) axial transmission techniques exploit the multimode waveguide response of long bones to yield estimates of cortical bone structure characteristics. This pilot cross-sectional study aimed to evaluate the performance at the one-third distal radius of a bidirectional axial transmission technique (BDAT) to discriminate between fractured and nonfractured postmenopausal women. Cortical thickness (Ct.Th) and porosity (Ct.Po) estimates were obtained for 201 postmenopausal women: 109 were nonfractured (62.6 ± 7.8 years), 92 with one or more nontraumatic fractures (68.8 ± 9.2 years), 17 with hip fractures (66.1 ± 10.3 years), 32 with vertebral fractures (72.4 ± 7.9 years), and 17 with wrist fractures (67.8 ± 9.6 years). The areal bone mineral density (aBMD) was obtained using DXA at the femur and spine. Femoral aBMD correlated weakly, but significantly with Ct.Th (R = 0.23, p < 0.001) and Ct.Po (R = -0.15, p < 0.05). Femoral aBMD and both US parameters were significantly different between the subgroup of all nontraumatic fractures combined and the control group (p < 0.05). The main findings were that (1) Ct.Po was discriminant for all nontraumatic fractures combined (OR = 1.39; area under the receiver operating characteristic curve [AUC] equal to 0.71), for vertebral (OR = 1.96; AUC = 0.84) and wrist fractures (OR = 1.80; AUC = 0.71), whereas Ct.Th was discriminant for hip fractures only (OR = 2.01; AUC = 0.72); there was a significant association (2) between increased Ct.Po and vertebral and wrist fractures when these fractures were not associated with any measured aBMD variables; (3) between increased Ct.Po and all nontraumatic fractures combined independently of aBMD neck; and (4) between decreased Ct.Th and hip fractures independently of aBMD femur. BDAT variables showed comparable performance to that of aBMD neck with all types of fractures (OR = 1.48; AUC = 0.72) and that of aBMD femur with hip fractures (OR = 2.21; AUC = 0.70). If these results are confirmed in prospective studies, cortical BDAT measurements may be considered useful for assessing fracture risk in postmenopausal women. © 2019 American Society for Bone and Mineral Research.
Collapse
Affiliation(s)
- J-G Minonzio
- Laboratoire d'Imagerie Biomédicale, Sorbonne Université, CNRS, INSERM, Paris, France
| | - N Bochud
- Laboratoire d'Imagerie Biomédicale, Sorbonne Université, CNRS, INSERM, Paris, France
| | - Q Vallet
- Laboratoire d'Imagerie Biomédicale, Sorbonne Université, CNRS, INSERM, Paris, France
| | - D Ramiandrisoa
- Laboratoire d'Imagerie Biomédicale, Sorbonne Université, CNRS, INSERM, Paris, France
| | - A Etcheto
- Department of Rheumatology, Cochin Hospital, Epidemiology and Biostatistics Sorbonne Paris Cité, Research Center, INSERM U1153, Paris Descartes University, Paris, France
| | - K Briot
- Department of Rheumatology, Cochin Hospital, Epidemiology and Biostatistics Sorbonne Paris Cité, Research Center, INSERM U1153, Paris Descartes University, Paris, France
| | - S Kolta
- Department of Rheumatology, Cochin Hospital, Epidemiology and Biostatistics Sorbonne Paris Cité, Research Center, INSERM U1153, Paris Descartes University, Paris, France
| | - C Roux
- Department of Rheumatology, Cochin Hospital, Epidemiology and Biostatistics Sorbonne Paris Cité, Research Center, INSERM U1153, Paris Descartes University, Paris, France
| | - P Laugier
- Laboratoire d'Imagerie Biomédicale, Sorbonne Université, CNRS, INSERM, Paris, France
| |
Collapse
|
34
|
Tello J, Roux C, Chouiki H, Laucou V, Sarah G, Weber A, Santoni S, Flutre T, Pons T, This P, Péros JP, Doligez A. A novel high-density grapevine (Vitis vinifera L.) integrated linkage map using GBS in a half-diallel population. Theor Appl Genet 2019; 132:2237-2252. [PMID: 31049634 DOI: 10.1007/s00122-019-03351-y] [Citation(s) in RCA: 20] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/15/2019] [Accepted: 04/20/2019] [Indexed: 05/21/2023]
Abstract
A half-diallel population involving five elite grapevine cultivars was generated and genotyped by GBS, and highly-informative segregation data was used to construct a high-density genetic map for Vitis vinifera L. Grapevine is one of the most relevant fruit crops in the world. Deeper genetic knowledge could assist modern grapevine breeding programs to develop new wine grape varieties able to face climate change effects. To assist in the rapid identification of markers for crop yield components, grape quality traits and adaptation potential, we generated a large Vitis vinifera L. population (N = 624) by crossing five red wine cultivars in a half-diallel scheme, which was subsequently sequenced by an efficient GBS procedure. A high number of fully informative genetic variants was detected using a novel mapping approach capable of reconstructing local haplotypes from adjacent biallelic SNPs, which were subsequently used to construct the densest consensus genetic map available for the cultivated grapevine to date. This 1378.3-cM map integrates 10 bi-parental consensus maps and orders 4437 markers in 3353 unique positions on 19 chromosomes. Markers are well distributed all along the grapevine reference genome, covering up to 98.8% of its genomic sequence. Additionally, a good agreement was observed between genetic and physical orders, adding confidence in the quality of this map. Collectively, our results pave the way for future genetic studies (such as fine QTL mapping) aimed to understand the complex relationship between genotypic and phenotypic variation in the cultivated grapevine. In addition, the method used (which efficiently delivers a high number of fully informative markers) could be of interest to other outbred organisms, notably perennial fruit crops.
Collapse
Affiliation(s)
- Javier Tello
- UMR AGAP, University of Montpellier-CIRAD-INRA-Montpellier SupAgro, Montpellier, France
- UMT Geno-Vigne®, IFV-INRA-Montpellier SupAgro, Montpellier, France
| | - Catherine Roux
- UMR AGAP, University of Montpellier-CIRAD-INRA-Montpellier SupAgro, Montpellier, France
- UMT Geno-Vigne®, IFV-INRA-Montpellier SupAgro, Montpellier, France
| | - Hajar Chouiki
- UMR AGAP, University of Montpellier-CIRAD-INRA-Montpellier SupAgro, Montpellier, France
| | - Valérie Laucou
- UMR AGAP, University of Montpellier-CIRAD-INRA-Montpellier SupAgro, Montpellier, France
- UMT Geno-Vigne®, IFV-INRA-Montpellier SupAgro, Montpellier, France
| | - Gautier Sarah
- UMR AGAP, University of Montpellier-CIRAD-INRA-Montpellier SupAgro, Montpellier, France
- UMT Geno-Vigne®, IFV-INRA-Montpellier SupAgro, Montpellier, France
| | - Audrey Weber
- UMR AGAP, University of Montpellier-CIRAD-INRA-Montpellier SupAgro, Montpellier, France
| | - Sylvain Santoni
- UMR AGAP, University of Montpellier-CIRAD-INRA-Montpellier SupAgro, Montpellier, France
| | - Timothée Flutre
- UMR AGAP, University of Montpellier-CIRAD-INRA-Montpellier SupAgro, Montpellier, France
- UMT Geno-Vigne®, IFV-INRA-Montpellier SupAgro, Montpellier, France
| | - Thierry Pons
- UMR AGAP, University of Montpellier-CIRAD-INRA-Montpellier SupAgro, Montpellier, France
- UMT Geno-Vigne®, IFV-INRA-Montpellier SupAgro, Montpellier, France
| | - Patrice This
- UMR AGAP, University of Montpellier-CIRAD-INRA-Montpellier SupAgro, Montpellier, France
- UMT Geno-Vigne®, IFV-INRA-Montpellier SupAgro, Montpellier, France
| | - Jean-Pierre Péros
- UMR AGAP, University of Montpellier-CIRAD-INRA-Montpellier SupAgro, Montpellier, France
- UMT Geno-Vigne®, IFV-INRA-Montpellier SupAgro, Montpellier, France
| | - Agnès Doligez
- UMR AGAP, University of Montpellier-CIRAD-INRA-Montpellier SupAgro, Montpellier, France.
- UMT Geno-Vigne®, IFV-INRA-Montpellier SupAgro, Montpellier, France.
| |
Collapse
|
35
|
Kolta S, Etcheto A, Fechtenbaum J, Feydy A, Roux C, Briot K. Measurement of Trabecular Bone Score of the Spine by Low-Dose Imaging System (EOS ®): A Feasibility Study. J Clin Densitom 2019; 22:243-248. [PMID: 30120025 DOI: 10.1016/j.jocd.2018.05.040] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/27/2018] [Revised: 05/23/2018] [Accepted: 05/23/2018] [Indexed: 10/28/2022]
Abstract
UNLABELLED Purpose/Introduction: Measurement of trabecular bone score (TBS®) of the lumbar spine on dual energy X-ray absorptiometry (DXA) devices improves fracture risk prediction. We conducted a proof of concept study to assess the feasibility of TBS® measured on the low-dose imaging system EOS®. METHODS TBS was assessed on both DXA and EOS® in 122 patients aged ≥ 50 yr, receiving no anti-osteoporotic treatment. The TBS® was computed on full-body EOS® images, focusing on the lumbar spine region. The patients were also scanned with a DXA bone densitometer (Hologic) and the spine and hip bone mineral density (g/cm²) were computed. RESULTS TBS® measurement on EOS® was not possible in 34 patients due to technical problems. It could be measured on both DXA and EOS® in 88 patients (28 with severe low-trauma fracture and 60 without fracture). TBS-EOS values were significantly lower in fractured patients compared to nonfractured patients. TBS-EOS was associated with the presence of fractures as reported by an AUC of 0.70. Odds ratio of TBS-EOS for the presence of severe low-trauma fracture was 2.00 [1.24-3.25], p = 0.005. CONCLUSIONS This proof of concept study, based on a prototype version of the TBS-EOS, demonstrated the feasibility of the measurement of TBS® on low-dose EOS® imaging devices. Results show that the TBS-EOS was lower in patients with severe low-trauma fractures compared to nonfractured patients independently from bone mineral density. Some technical issues need to be solved before its eventual use in routine clinical settings. Additional prospective studies are still needed to define the actual contribution of this new technique.
Collapse
Affiliation(s)
- S Kolta
- Department of Rheumatology, Cochin Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France; INSERM UMR-1153, Paris, France.
| | | | | | - A Feydy
- INSERM UMR-1153, Paris, France; Department of Radiology B, Cochin Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France; Paris-Descartes University, Paris, France
| | - C Roux
- Department of Rheumatology, Cochin Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France; INSERM UMR-1153, Paris, France; Paris-Descartes University, Paris, France
| | - K Briot
- Department of Rheumatology, Cochin Hospital, Assistance Publique-Hôpitaux de Paris, Paris, France; INSERM UMR-1153, Paris, France
| |
Collapse
|
36
|
Che H, Breuil V, Cortet B, Paccou J, Thomas T, Chapuis L, Debiais F, Mehsen-Cetre N, Javier RM, Loiseau Peres S, Roux C, Briot K. Vertebral fractures cascade: potential causes and risk factors. Osteoporos Int 2019; 30:555-563. [PMID: 30519756 DOI: 10.1007/s00198-018-4793-1] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/28/2018] [Accepted: 11/29/2018] [Indexed: 12/11/2022]
Abstract
UNLABELLED We performed a study to identify potential causes and risk factors of vertebral fracture cascade. Vertebral fracture cascade is a severe clinical event in patients with bone fragility. Only half of patients have an identified cause of secondary osteoporosis. INTRODUCTION Vertebral fracture (VF) is the most common osteoporotic fracture, and a strong risk factor of subsequent VFs leading to VF cascade (VFC). We prompted a study to identify potential causes and risk factors of VFC. METHODS VFC observations were collected retrospectively between January 2016 and April 2017. VFC was defined as an occurrence of at least three VFs within 1 year. RESULTS We included in 10 centers a total of 113 patients with VFC (79.6% of women, median age 73, median number of VFs in the cascade, 5). We observed 40.5% and 30.9% of patients with previous major fractures and a previous VF, respectively, and 68.6% with densitometric osteoporosis; 18.9% of patients were currently receiving oral glucocorticoids and 37.1% in the past. VFC was attributed by the physician to postmenopausal osteoporosis in 54% of patients. A secondary osteoporosis associated with the VFC was diagnosed in 52 patients: glucocorticoid-induced osteoporosis (25.7%), non-malignant hemopathies (6.2%), alcoholism (4.4%), use of aromatase inhibitors (3.6%), primary hyperparathyroidism (2.7%), hypercorticism (2.7%), anorexia nervosa (2.7%), and pregnancy and lactation-associated osteoporosis (1.8%). A total of 11.8% of cases were reported following a vertebroplasty procedure. A total of 31.5% patients previously received an anti-osteoporotic treatment. In six patients, VFC occurred early after discontinuation of an anti-osteoporotic treatment, in the year after the last dose effect was depleted: five after denosumab and one after odanacatib. CONCLUSION The results of this retrospective study showed that only half of VFC occurred in patients with a secondary cause of osteoporosis. Prospective studies are needed to further explore the determinants of this severe complication of osteoporosis.
Collapse
Affiliation(s)
- H Che
- Rheumatology Department, CHU Lapeyronie Montpellier, 371 avenue du Gaston Giraud, 34090, Montpellier, France.
| | - V Breuil
- Department of Rheumatology, BIAM - UMR E 4320 TIRO-MATOs CEA/UNS, Université Côte D'Azur, Centre Hospitalier Universitaire Nice, Nice, France
| | - B Cortet
- Service de rhumatologie, CHRU France et Université de Lille, Université Littoral Côte d'Opale, 59000 Lille, PMOI EA 4490 faculté de chirurgie dentaire, place de Verdun, 59000, Lille, France
| | - J Paccou
- Service de rhumatologie, CHRU France et Université de Lille, Université Littoral Côte d'Opale, 59000 Lille, PMOI EA 4490 faculté de chirurgie dentaire, place de Verdun, 59000, Lille, France
| | - T Thomas
- Rheumatology Department, CHU de Saint Etienne, INSERM U1059, Lab Biologie Intégrée du Tissu Osseux, Université de Lyon, 42055, Saint-Etienne Cedex 2, France
| | - L Chapuis
- Rheumatology Department, CH Simone Veil du Vitre, 30 route de Rennes, 35500, Vitre, France
| | - F Debiais
- Rheumatology Department, CHU La Miletrie Poitiers, 2 rue de la Miletrie, 86021, Poitiers Cedex, France
| | - N Mehsen-Cetre
- Rheumatology Department, CHU Pellegrin Bordeaux, Rue de la pelouse de Douet, 33000, Bordeaux, France
| | - R M Javier
- Rheumatology Department, Hôpitaux Universitaires de Strasbourg, 1 avenue Moliere, 67098, Strasbourg, France
| | - S Loiseau Peres
- Rheumatology Department, CHR Orléans, 14 avenue de l'Hopital, 45000, Orleans, France
| | - C Roux
- Rheumatology Department, INSERM 1153, CHU Paris Cochin, Paris Descartes University, 27 rue du Faubourg Saint-Jacques, 75014, Paris, France
| | - K Briot
- Rheumatology Department, INSERM 1153, CHU Paris Cochin, Paris Descartes University, 27 rue du Faubourg Saint-Jacques, 75014, Paris, France
| |
Collapse
|
37
|
Henriquez S, Dunogué B, Régent A, Cohen P, Berezne A, Le Jeunne C, Mouthon L, Roux C, Guillevin L, Briot K, Terrier B. Le tissu adipeux abdominal prédit la survenue d’évènements cardiovasculaires majeurs au cours des vascularites nécrosantes : étude prospective de 120 patients. Rev Med Interne 2018. [DOI: 10.1016/j.revmed.2018.10.322] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
38
|
Brément T, Cossec C, Roux C, Knol AC, Dréno B, Khammari A, Bourdeau P, Bruet V. Expression of Three Adipokines (Adiponectin, Leptin and Resistin) in Normal Canine Skin: a Pilot Study. J Comp Pathol 2018; 167:82-90. [PMID: 30503576 DOI: 10.1016/j.jcpa.2018.10.179] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/05/2018] [Revised: 10/17/2018] [Accepted: 10/26/2018] [Indexed: 01/19/2023]
Abstract
Adipokines are biologically active cytokines that are mainly produced in adipose tissue. There is evidence, in man and mice, that some adipokines may be secreted in other tissues including the vascular endothelium, epithelia and sebaceous glands. Moreover, modified serum levels of adipokines have been detected in people with acne vulgaris or psoriasis; it is suspected that adipokines could contribute to local and systemic inflammatory conditions. We aimed to evaluate the expression of three adipokines (i.e. leptin, adiponectin and resistin) in normal canine skin. Formalin-fixed, paraffin wax-embedded punch biopsy samples were obtained from the sparsely-haired skin of the caudal ventral abdomen of a single clinically healthy dog with no history of skin disease. Immunohistochemistry was applied, using rabbit polyclonal primary antibodies specific for leptin, adiponectin and resistin. Adipokines were not expressed in normal canine dermis or hypodermis. In contrast, they were detected in the keratinocytes of all epidermal layers and hair follicle segments, sebocytes, apocrine gland cells and in the vascular endothelium. This is the first report on the expression of adipokines in normal canine skin, a first step in studying their role in the skin physiology and inflammatory skin diseases of dogs.
Collapse
Affiliation(s)
- T Brément
- Dermatology/Parasitology/Mycology Unit, School of Veterinary Medicine-ONIRIS, University of Nantes, CS 40706, Nantes, France
| | - C Cossec
- NP3 Unit, School of Veterinary Medicine-ONIRIS, University of Nantes, CS 40706, Nantes 44307, France
| | - C Roux
- Dermatology/Parasitology/Mycology Unit, School of Veterinary Medicine-ONIRIS, University of Nantes, CS 40706, Nantes, France
| | - A C Knol
- CRCINA, INSERM, University of Angers, University of Nantes, Nantes, France
| | - B Dréno
- CRCINA, INSERM, University of Angers, University of Nantes, Nantes, France; Dermatology Service, CIC1413, CHU Nantes, Nantes, France
| | - A Khammari
- CRCINA, INSERM, University of Angers, University of Nantes, Nantes, France; Dermatology Service, CIC1413, CHU Nantes, Nantes, France
| | - P Bourdeau
- Dermatology/Parasitology/Mycology Unit, School of Veterinary Medicine-ONIRIS, University of Nantes, CS 40706, Nantes, France; NP3 Unit, School of Veterinary Medicine-ONIRIS, University of Nantes, CS 40706, Nantes 44307, France
| | - V Bruet
- Dermatology/Parasitology/Mycology Unit, School of Veterinary Medicine-ONIRIS, University of Nantes, CS 40706, Nantes, France; NP3 Unit, School of Veterinary Medicine-ONIRIS, University of Nantes, CS 40706, Nantes 44307, France.
| |
Collapse
|
39
|
Montis C, Till U, Vicendo P, Roux C, Mingotaud AF, Violleau F, Demazeau M, Berti D, Lonetti B. Extended photo-induced endosome-like structures in giant vesicles promoted by block-copolymer nanocarriers. Nanoscale 2018; 10:15442-15446. [PMID: 30091780 DOI: 10.1039/c8nr04355h] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/25/2023]
Abstract
Upon irradiation, the photosensitizer pheophorbide-a causes dramatic morphological transitions in giant unilamellar lipid vesicles. This endocytosis-like process occurs only when the photoactive species are encapsulated in a copolymer nanocarrier and strictly depends on the chemical nature of the copolymer. Altogether, these results open up new perspectives in the field of photo-chemical internalization mediated by nanoassemblies.
Collapse
Affiliation(s)
- C Montis
- Department of Chemistry "Ugo Schiff", University of Florence and CSGI, Via della Lastruccia 3, 50019 Sesto Fiorentino Firenze, Italy
| | | | | | | | | | | | | | | | | |
Collapse
|
40
|
Magnani C, Montis C, Mangiapia G, Mingotaud AF, Mingotaud C, Roux C, Joseph P, Berti D, Lonetti B. Hybrid vesicles from lipids and block copolymers: Phase behavior from the micro- to the nano-scale. Colloids Surf B Biointerfaces 2018; 168:18-28. [DOI: 10.1016/j.colsurfb.2018.01.042] [Citation(s) in RCA: 21] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/02/2017] [Revised: 12/21/2017] [Accepted: 01/20/2018] [Indexed: 12/18/2022]
|
41
|
Barral M, Roux C, Guerrache Y, Foucher R, Dautry R, Dohan A. Intrathoracic pancreatic herniation: A rare cause of acute pancreatitis. Diagn Interv Imaging 2018; 99:673-674. [PMID: 29705159 DOI: 10.1016/j.diii.2018.04.002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/28/2018] [Accepted: 04/06/2018] [Indexed: 10/17/2022]
Affiliation(s)
- M Barral
- Université Paris-Descartes, Sorbonne Paris-Cité, 12, rue de l'École de Médecine, 75006 Paris, France; Department of Abdominal and Interventional Imaging, Hôpital Cochin, Assistance publique-Hôpitaux de Paris, 27, rue du Faubourg-Saint-Jacques, 75014 Paris, France.
| | - C Roux
- Department of Body and Interventional Imaging, Hôpital Lariboisière, Assistance publique-Hôpitaux de Paris, 2, rue Ambroise-Paré, 75475 Paris, France.
| | - Y Guerrache
- Department of Body and Interventional Imaging, Hôpital Lariboisière, Assistance publique-Hôpitaux de Paris, 2, rue Ambroise-Paré, 75475 Paris, France.
| | - R Foucher
- Department of Body and Interventional Imaging, Hôpital Lariboisière, Assistance publique-Hôpitaux de Paris, 2, rue Ambroise-Paré, 75475 Paris, France.
| | - R Dautry
- Department of Abdominal and Interventional Imaging, Hôpital Cochin, Assistance publique-Hôpitaux de Paris, 27, rue du Faubourg-Saint-Jacques, 75014 Paris, France.
| | - A Dohan
- Université Paris-Descartes, Sorbonne Paris-Cité, 12, rue de l'École de Médecine, 75006 Paris, France; Department of Abdominal and Interventional Imaging, Hôpital Cochin, Assistance publique-Hôpitaux de Paris, 27, rue du Faubourg-Saint-Jacques, 75014 Paris, France.
| |
Collapse
|
42
|
Affiliation(s)
- M. Maitre
- Centre for Forensic Science, University of Technology Sydney, Sydney, Australia
| | - K. P. Kirkbride
- School of Chemical and Physical Sciences, Flinders University, Adelaide, Australia
| | - M. Horder
- Forensic Ballistics Investigation Section, Forensic Services Group, NSW Police Force, Surry Hills, Australia
| | - C. Roux
- Centre for Forensic Science, University of Technology Sydney, Sydney, Australia
| | - A. Beavis
- Centre for Forensic Science, University of Technology Sydney, Sydney, Australia
| |
Collapse
|
43
|
Chattaragada MS, Riganti C, Sassoe M, Principe M, Santamorena MM, Roux C, Curcio C, Evangelista A, Allavena P, Salvia R, Rusev B, Scarpa A, Cappello P, Novelli F. FAM49B, a novel regulator of mitochondrial function and integrity that suppresses tumor metastasis. Oncogene 2018; 37:697-709. [PMID: 29059164 PMCID: PMC5808099 DOI: 10.1038/onc.2017.358] [Citation(s) in RCA: 42] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/27/2017] [Revised: 08/07/2017] [Accepted: 08/12/2017] [Indexed: 12/13/2022]
Abstract
Mitochondrial dysregulation plays a central role in cancers and drives reactive oxygen species (ROS)-dependent tumor progression. We investigated the pro-tumoral roles of mitochondrial dynamics and altered intracellular ROS levels in pancreatic ductal adenocarcinoma (PDAC). We identified 'family with sequence similarity 49 member B' (FAM49B) as a mitochondria-localized protein that regulates mitochondrial fission and cancer progression. Silencing FAM49B in PDAC cells resulted in increased fission and mitochondrial ROS generation, which enhanced PDAC cell proliferation and invasion. Notably, FAM49B expression levels in PDAC cells were downregulated by the tumor microenvironment. Overall, the results of this study show that FAM49B acts as a suppressor of cancer cell proliferation and invasion in PDAC by regulating tumor mitochondrial redox reactions and metabolism.
Collapse
Affiliation(s)
- M S Chattaragada
- Department of Molecular Biotechnology and Health Sciences, University of Turin, Turin, Italy
- Center for Experimental Research and Medical Studies, Azienda Universitaria Ospedaliera Città della Salute e della Scienza di Torino, Turin, Italy
| | - C Riganti
- Department of Oncology, University of Turin, Turin, Italy
| | - M Sassoe
- Department of Neurosciences, ‘Rita Levi Montalcini’, University of Turin, Turin, Italy
| | - M Principe
- Department of Molecular Biotechnology and Health Sciences, University of Turin, Turin, Italy
- Center for Experimental Research and Medical Studies, Azienda Universitaria Ospedaliera Città della Salute e della Scienza di Torino, Turin, Italy
| | - M M Santamorena
- Department of Molecular Biotechnology and Health Sciences, University of Turin, Turin, Italy
- Center for Experimental Research and Medical Studies, Azienda Universitaria Ospedaliera Città della Salute e della Scienza di Torino, Turin, Italy
| | - C Roux
- Department of Molecular Biotechnology and Health Sciences, University of Turin, Turin, Italy
- Center for Experimental Research and Medical Studies, Azienda Universitaria Ospedaliera Città della Salute e della Scienza di Torino, Turin, Italy
| | - C Curcio
- Department of Molecular Biotechnology and Health Sciences, University of Turin, Turin, Italy
- Center for Experimental Research and Medical Studies, Azienda Universitaria Ospedaliera Città della Salute e della Scienza di Torino, Turin, Italy
| | - A Evangelista
- Department of Clinical Epidemiology, Azienda Universitaria Ospedaliera Città della Salute e della Scienza and CPO Piemonte, Turin, Italy
| | - P Allavena
- Laboratory of Molecular Gastroenterology, Department of Gastroenterology, Humanitas Clinical and Research Center, Milan, Italy
| | - R Salvia
- Department of Surgery, The Pancreas Institute, University and Hospital Trust of Verona, Verona, Italy
| | - B Rusev
- Department of Pathology and Public Health & ARC-NET Research Center, University and Hospital Trust of Verona, Verona, Italy
| | - A Scarpa
- Department of Pathology and Public Health & ARC-NET Research Center, University and Hospital Trust of Verona, Verona, Italy
| | - P Cappello
- Department of Molecular Biotechnology and Health Sciences, University of Turin, Turin, Italy
- Center for Experimental Research and Medical Studies, Azienda Universitaria Ospedaliera Città della Salute e della Scienza di Torino, Turin, Italy
- Molecular Biotechnology Center, University of Turin, Turin, Italy
| | - F Novelli
- Department of Molecular Biotechnology and Health Sciences, University of Turin, Turin, Italy
- Center for Experimental Research and Medical Studies, Azienda Universitaria Ospedaliera Città della Salute e della Scienza di Torino, Turin, Italy
- Molecular Biotechnology Center, University of Turin, Turin, Italy
| |
Collapse
|
44
|
Pellerin J, Alsaleh A, Mermillod P, Souza-Fabjan J, Rodolakis A, Rousset E, Dubreil L, Bruyas J, Roux C, Fieni F. Attachment of Coxiella burnetii to the zona pellucida of in vitro produced goat embryos. Theriogenology 2018; 106:259-264. [DOI: 10.1016/j.theriogenology.2017.10.033] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/19/2017] [Revised: 10/23/2017] [Accepted: 10/23/2017] [Indexed: 11/16/2022]
|
45
|
Gaume M, Marie-Hardy L, Larousserie F, Lavielle M, Roux C, Leclerc P, Paugam A, Archambeau D, Eyrolle L, Gauzit R, Lortholary O, Anract P, Epelboin L, Salmon D. [Erratum to "Histoplasma capsulatum bone and joint infection" [Med. Mal. Infect. 47 (2017) 554-557]]. Med Mal Infect 2017; 48:81. [PMID: 29274666 DOI: 10.1016/j.medmal.2017.12.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
Affiliation(s)
- M Gaume
- Département de chirurgie orthopédique, hôpital Cochin, université Paris Descartes, Sorbonne Paris Cité, Assistance publique-Hôpitaux de Paris, Paris, France.
| | - L Marie-Hardy
- Département de chirurgie orthopédique, hôpital Cochin, université Paris Descartes, Sorbonne Paris Cité, Assistance publique-Hôpitaux de Paris, Paris, France
| | - F Larousserie
- Département de pathologie, hôpital Cochin, université Paris Descartes, Sorbonne Paris Cité, Assistance publique-Hôpitaux de Paris, Paris, France
| | - M Lavielle
- Département de rhumatologie, hôpital Cochin, université Paris Descartes, Sorbonne Paris Cité, Assistance publique-Hôpitaux de Paris, Paris, France
| | - C Roux
- Département de rhumatologie, hôpital Cochin, université Paris Descartes, Sorbonne Paris Cité, Assistance publique-Hôpitaux de Paris, Paris, France
| | - P Leclerc
- Département de chirurgie orthopédique, hôpital Cochin, université Paris Descartes, Sorbonne Paris Cité, Assistance publique-Hôpitaux de Paris, Paris, France
| | - A Paugam
- Département de parasitologie-mycologie, hôpital Cochin, université Paris Descartes, Sorbonne Paris Cité, Assistance publique-Hôpitaux de Paris, Paris, France
| | - D Archambeau
- Département d'anesthésie, hôpital Cochin, université Paris Descartes, Sorbonne Paris Cité, Assistance publique-Hôpitaux de Paris, Paris, France
| | - L Eyrolle
- Département d'anesthésie, hôpital Cochin, université Paris Descartes, Sorbonne Paris Cité, Assistance publique-Hôpitaux de Paris, Paris, France
| | - R Gauzit
- Département de maladies infectieuses, hôpital Cochin, université Paris Descartes, Sorbonne Paris Cité, Assistance publique-Hôpitaux de Paris, Paris, France
| | - O Lortholary
- Département de maladies infectieuses, hôpital Necker, université Paris Descartes, Sorbonne Paris Cité, Assistance publique-Hôpitaux de Paris, Paris, France
| | - P Anract
- Département de chirurgie orthopédique, hôpital Cochin, université Paris Descartes, Sorbonne Paris Cité, Assistance publique-Hôpitaux de Paris, Paris, France
| | - L Epelboin
- Infectious Diseases Department, centre hospitalier Andrée-Rosemon, Cayenne, France
| | - D Salmon
- Département de maladies infectieuses, hôpital Cochin, université Paris Descartes, Sorbonne Paris Cité, Assistance publique-Hôpitaux de Paris, Paris, France
| |
Collapse
|
46
|
Voillemot M, Rougemont Q, Roux C, Pannell JR. The divergence history of the perennial plant Linaria cavanillesii
confirms a recent loss of self-incompatibility. J Evol Biol 2017; 31:136-147. [DOI: 10.1111/jeb.13209] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/23/2017] [Revised: 11/03/2017] [Accepted: 11/07/2017] [Indexed: 11/30/2022]
Affiliation(s)
- M. Voillemot
- Department of Ecology and Evolution; Biophore/Sorge; University of Lausanne; Lausanne Switzerland
| | - Q. Rougemont
- Institut de Biologie Intégrative et des Systèmes (IBIS); University of Laval; Québec City Québec Canada
| | - C. Roux
- Department of Ecology and Evolution; Biophore/Sorge; University of Lausanne; Lausanne Switzerland
- Unité Evo-Eco-Paléo (EEP) - UMR 8198; CNRS; Université de Lille Sciences et Technologies; Villeneuve d'Ascq Cedex France
| | - J. R. Pannell
- Department of Ecology and Evolution; Biophore/Sorge; University of Lausanne; Lausanne Switzerland
| |
Collapse
|
47
|
Litwic AE, Compston JE, Wyman A, Siris ES, Gehlbach SH, Adachi JD, Chapurlat R, Díez-Pérez A, LaCroix AZ, Nieves JW, Netelenbos JC, Pfeilschifter J, Rossini M, Roux C, Saag KG, Silverman S, Watts NB, Greenspan SL, March L, Gregson CL, Cooper C, Dennison EM. Self-perception of fracture risk: what can it tell us? Osteoporos Int 2017; 28:3495-3500. [PMID: 28861636 PMCID: PMC5759929 DOI: 10.1007/s00198-017-4200-3] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/16/2017] [Accepted: 08/16/2017] [Indexed: 11/28/2022]
Abstract
UNLABELLED In this study, we report that self-perception of fracture risk captures some aspect of fracture risk not currently measured using conventional fracture prediction tools and is associated with improved medication uptake. It suggests that adequate appreciation of fracture risk may be beneficial and lead to greater healthcare engagement and treatment. INTRODUCTION This study aimed to assess how well self-perception of fracture risk, and fracture risk as estimated by the fracture prediction tool FRAX, related to fracture incidence and uptake and persistence of anti-osteoporosis medication among women participating in the Global Longitudinal study of Osteoporosis in Women (GLOW). METHODS GLOW is an international cohort study involving 723 physician practices across 10 countries in Europe, North America and Australia. Aged ≥ 55 years, 60,393 women completed baseline questionnaires detailing medical history, including co-morbidities, fractures and self-perceived fracture risk (SPR). Annual follow-up included self-reported incident fractures and anti-osteoporosis medication (AOM) use. We calculated FRAX risk without bone mineral density measurement. RESULTS Of the 39,241 women with at least 1 year of follow-up data, 2132 (5.4%) sustained an incident major osteoporotic fracture over 5 years of follow-up. Within each SPR category, risk of fracture increased as the FRAX categorisation of risk increased. In GLOW, only 11% of women with a lower baseline SPR were taking AOM at baseline, compared with 46% of women with a higher SPR. AOM use tended to increase in the years after a reported fracture. However, women with a lower SPR who were fractured still reported lower AOM rates than women with or without a fracture but had a higher SPR. CONCLUSIONS These results suggest that SPR captures some aspect of fracture risk not currently measured using conventional fracture prediction tools and is also associated with improved medication uptake.
Collapse
Affiliation(s)
- A E Litwic
- MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton General Hospital, Southampton, SO16 6YD, UK
| | | | - A Wyman
- Center for Outcomes Research, University of Massachusetts Medical School, Worcester, MA, USA
| | - E S Siris
- Department of Medicine, Columbia University Medical Center, New York, NY, USA
| | - S H Gehlbach
- Center for Outcomes Research, University of Massachusetts Medical School, Worcester, MA, USA
| | - J D Adachi
- St. Joseph's Hospital, McMaster University, Hamilton, Ontario, Canada
| | - R Chapurlat
- INSERM U831, Division of Rheumatology, Hôpital E. Herriot, Université de Lyon, Lyon, France
| | - A Díez-Pérez
- Hospital del Mar-IMIM-Autonomous, University of Barcelona, Barcelona, Spain
| | - A Z LaCroix
- Fred Hutchinson Cancer Research Center, Seattle, WA, USA
| | - J W Nieves
- Helen Hayes Hospital and Columbia University, West Haverstraw, NY, USA
| | - J C Netelenbos
- Department of Endocrinology, VU University Medical Center, Amsterdam, The Netherlands
| | - J Pfeilschifter
- Department of Internal Medicine III, Alfried Krupp Krankenhaus, Essen, Germany
| | - M Rossini
- Department of Rheumatology, University of Verona, Verona, Italy
| | - C Roux
- Cochin Hospital, Paris Descartes University, Paris, France
| | - K G Saag
- University of Alabama-Birmingham, Birmingham, AL, USA
| | - S Silverman
- Department of Rheumatology, Cedars-Sinai/UCLA, Los Angeles, CA, USA
| | - N B Watts
- Bone Health and Osteoporosis Center, University of Cincinnati, Cincinnati, OH, USA
| | | | - L March
- Faculty of Medicine and Department of Public Health, University of Sydney, Sydney, Australia
| | - C L Gregson
- MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton General Hospital, Southampton, SO16 6YD, UK
- Musculoskeletal Research Unit, Learning and Research Building, Southmead Hospital, University of Bristol, Bristol, UK
| | - C Cooper
- MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton General Hospital, Southampton, SO16 6YD, UK
- Institute of Musculoskeletal Sciences, University of Oxford, Oxford, UK
| | - E M Dennison
- MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton General Hospital, Southampton, SO16 6YD, UK.
| | | |
Collapse
|
48
|
Roux C, Baron G, Briot K, Roux B, Cortet B, Thomas T. Management of oral bisphosphonates treatment by rheumatologists and determinants of therapeutic changes: a case-vignette-based study. Osteoporos Int 2017; 28:3339-3345. [PMID: 28852785 DOI: 10.1007/s00198-017-4188-8] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/20/2017] [Accepted: 08/01/2017] [Indexed: 10/19/2022]
Abstract
UNLABELLED Using case vignette methodology, this study shows that only 4% of patients are maintained on oral bisphosphonates over 5 years, and prescribers switch or stop the treatment in 20-30% of cases at each visit. There are few determinants of these changes. More information on appropriate follow-up could help in patients' management. INTRODUCTION Persistence to oral bisphosphonates, the most commonly prescribed anti-osteoporotic treatments, is low. The aim of this study was to evaluate the role of rheumatologists on the treatment patterns, and to assess the determinants of treatment changes. METHODS We used the methodology of case vignettes with the participation of 142 rheumatologists. Three baseline clinical vignettes were presented: (1) the physician was asked to indicate the most appropriate period to schedule the next visit over 5 years, (2) the physician was tested about parameters for follow-up (including traps), and (3) various results (both clinical, biological, densitometric, and radiological) were given by random and analyzed as determinants of treatment changes. RESULTS The study allowed assessment of 426 virtual clinical cases. Clinical examinations, patient's height, inquiries about falls, and adherence to treatment were deemed necessary in > 90% of cases. Bone mineral density was measured in 22, 40, and 71% of cases at 2, 3, and 5 years, respectively. Dental follow-up was recommended in less than 25% of cases. Only 4.2% of patients were maintained on the same treatment at 5 years, and a change of treatment (stop or switch) occurs in 20-30% of cases at each visit. Significant determinants were adherence to treatment, serum C-terminal crosslinking telopeptide of type 1 collagen (CTX) value, change in patient's height, and the occurrence of an incident vertebral fracture. CONCLUSION Our study shows that maintenance of oral bisphosphonate in postmenopausal women managed by rheumatologists is low; there are few determinants of these changes and more information on appropriate follow-up could help in patients' management.
Collapse
Affiliation(s)
- C Roux
- Paris Descartes University, Paris, France.
- Department of Rheumatology, Cochin Hospital, Assistance Publique - Hôpitaux de Paris, 27, Rue du Faubourg St Jacques, 75014, Paris, France.
- INSERM UMR1153, Paris, France.
| | - G Baron
- Paris Descartes University, Paris, France
- INSERM UMR1153, Paris, France
- Biostatistics and Clinical Epidemiology Center - Hotel-Dieu Hospital, Assistance Publique - Hôpitaux de Paris, Paris, France
| | - K Briot
- Department of Rheumatology, Cochin Hospital, Assistance Publique - Hôpitaux de Paris, 27, Rue du Faubourg St Jacques, 75014, Paris, France
- INSERM UMR1153, Paris, France
| | - B Roux
- Fast 4 - Contract Research Organisation, Nîmes, France
| | - B Cortet
- Department of Rheumatology, Lille 2 - University, CHRU, Lille, France
- EA 4490, Lille, France
| | - T Thomas
- Department of Rheumatology, CHU, Saint-Etienne University, Saint-Etienne, France
- INSERM U1059, Saint-Etienne, France
| |
Collapse
|
49
|
Abstract
Systemic osteoporosis and increased fracture rates have been described in chronic inflammatory diseases such as rheumatoid arthritis, spondyloarthritis, systemic lupus erythematosus, inflammatory bowel diseases, and chronic obstructive pulmonary disease. Most of these patients receive glucocorticoids, which have their own deleterious effects on bone. However, the other main determinant of bone fragility is the inflammation itself, as shown by the interactions between the inflammatory mediators, the actors of the immune system, and the bone remodelling. The inflammatory disease activity is thus on top of the other well-known osteoporotic risk factors in these patients. Optimal control of inflammation is part of the prevention of osteoporosis, and potent anti-inflammatory drugs have positive effects on surrogate markers of bone fragility. More data are needed to assess the anti-fracture efficacy of a tight control of inflammation in patients with a chronic inflammatory disorder. This review aimed at presenting different clinical aspects of inflammatory diseases which illustrate the relationships between inflammation and bone fragility.
Collapse
Affiliation(s)
- K Briot
- Department of Rheumatology, Cochin Hospital, Assistance-Publique-Hôpitaux de Paris, Paris, France.
- Hôpital Cochin, Service de Rhumatologie, 27, Rue du Faubourg, St. Jacques, 75014, Paris, France.
- INSERM UMR 1153, Paris, France.
| | - P Geusens
- Department of Internal Medicine, Subdivision of Rheumatology, Maastricht University Medical Center, Maastricht, The Netherlands
- Hasselt University, Hasselt, Belgium
| | - I Em Bultink
- Department of Rheumatology, Amsterdam Rheumatology and Immunology Center, VU University Medical Center, Amsterdam, The Netherlands
| | - W F Lems
- Department of Rheumatology, Amsterdam Rheumatology and Immunology Center, VU University Medical Center, Amsterdam, The Netherlands
| | - C Roux
- Department of Rheumatology, Cochin Hospital, Assistance-Publique-Hôpitaux de Paris, Paris, France
- Hôpital Cochin, Service de Rhumatologie, 27, Rue du Faubourg, St. Jacques, 75014, Paris, France
- INSERM UMR 1153, Paris, France
- Paris Descartes University, Paris, France
| |
Collapse
|
50
|
Laroche M, Talibart M, Cormier C, Roux C, Guggenbuhl P, Degboe Y. Pregnancy-related fractures: a retrospective study of a French cohort of 52 patients and review of the literature. Osteoporos Int 2017; 28:3135-3142. [PMID: 28879474 DOI: 10.1007/s00198-017-4165-2] [Citation(s) in RCA: 29] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/15/2016] [Accepted: 07/17/2017] [Indexed: 12/14/2022]
Abstract
UNLABELLED A retrospective, multicentre study involving 52 patients was carried out to define the causes and characteristics of pregnancy-related osteoporosis. The mean number of vertebral fractures occurring during the last trimester of pregnancy or at the time of delivery was 3.8. This is often promoted by risk factors before or during pregnancy. INTRODUCTION In order to define the causes or predisposing factors of pregnancy-related osteoporosis and its clinical, radiological and bone density characteristics, laboratory findings, course and outcome, we carried out a retrospective multicentre study. METHODS The records of 52 women hospitalised over the last 10 years in the rheumatology departments of six French university hospitals and with a diagnosis of pregnancy-related osteoporosis were examined. RESULTS The patients' mean age at time of fracture was 32.1 years. In 10 patients, the fractures had occurred during the last trimester of pregnancy, and in 36 at the time of delivery or during the first 2 months post-partum. The mean number of vertebral fractures was 3.8 ± 2.0. Thirty three of the 52 patients had a risk factor of low bone mass before pregnancy. Twelve had disorders or treatments (heparin) that might promote osteoporosis during pregnancy, while 14 had no trigger factors before or during pregnancy. Overall, phosphate and calcium levels were normal, except for hyperphosphoraemia in lactating women (90%). On DXA scan, osteoporosis predominated in the trabecular bone (spinal T-score - 3.4, hip T-score - 2). Only 10 patients had a repeat fracture, and the increase in bone mineral density during follow-up was considerable, and improved by bisphosphonates (annual gain + 10% in the spine) or teriparatide (+ 15%). CONCLUSIONS Pregnancy-related osteoporosis gives rise to multiple vertebral fractures. It is often promoted by risk factors before or during pregnancy. Its mechanism is still unknown. Treatment with bisphosphonates or teriparatide appears to improve the recovery of bone mineral density.
Collapse
Affiliation(s)
- M Laroche
- Department of Rheumatology, Toulouse University Hospital, Toulouse, France.
- Centre de Rhumatologie, Hôpital Pierre Paul Riquet, CHU Purpan, 1 place du Dr Baylac, 31059, Toulouse Cedex, France.
| | - M Talibart
- Department of Rheumatology, Toulouse University Hospital, Toulouse, France
| | - C Cormier
- Department of Rheumatology, Cochin University Hospital, Paris, France
| | - C Roux
- Department of Rheumatology, Cochin University Hospital, Paris, France
| | - P Guggenbuhl
- Department of Rheumatology, Rennes University Hospital, Amiens, France
| | - Y Degboe
- Department of Rheumatology, Toulouse University Hospital, Toulouse, France
| |
Collapse
|